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ABSTRACT OF DISSERTATION

NOVEL COMPUTATIONAL METHODS
FOR CANCER GENOMICS DATA ANALYSIS
Cancer is a genetic disease responsible for one in eight deaths worldwide. The
advancement of next-generation sequencing (NGS) technology has revolutionized the
cancer research, allowing comprehensively profiling the cancer genome at great resolution.
Large-scale cancer genomics research has sparked the needs for efficient and accurate
Bioinformatics methods to analyze the data. The research presented in this dissertation
focuses on three areas in cancer genomics: cancer somatic mutation detection; cancer
driver genes identification and transcriptome profiling on single-cell level.
NGS data analysis involves a series of complicated data transformation that convert
raw sequencing data to the information that is interpretable by cancer researchers. The first
project in the dissertation established a robust, reproducible and scalable cancer genomics
data analysis workflow management system that automates the best practice mutation
calling pipelines to detect somatic single nucleotide polymorphisms, insertion, deletion and
copy number variation from NGS data. It integrates mutation annotation, clinically
actionable therapy prediction and data visualization that streamlines the sequence-to-report
data transformation.
In order to differentiate the driver mutations buried among a vast pool of passenger
mutations from a somatic mutation calling project, we developed MEScan in the second
project, a novel method that enables genome-scale driver mutations identification based on
mutual exclusivity test using cancer somatic mutation data. MEScan implements an
efficient statistical framework to de novo screen mutual exclusive patterns and in the
meantime taking into account the patient-specific and gene-specific background mutation
rate and adjusting the heterogenous mutation frequency. It outperforms several existing
methods based on simulation studies and real-world datasets. Genome-wide screening
using existing TCGA somatic mutation data discovers novel cancer-specific and pancancer mutually exclusive patterns.
Bulk RNA sequencing (RNA-Seq) has become one of the most commonly used
techniques for transcriptome profiling in a wide spectrum of biomedical and biological
research. Analyzing bulk RNA-Seq reads to quantify expression at each gene locus is the
first step towards the identification of differentially expressed genes for downstream
biological interpretation. Recent advances in single-cell RNA-seq (scRNA-seq)

technology allows cancer biologists to profile gene expression on higher resolution cellular
level. Preprocessing scRNA-seq data to quantify UMI-based gene count is the key to
characterize intra-tumor cellular heterogeneity and identify rare cells that governs tumor
progression, metastasis and treatment resistance. Despite its popularity, summarizing gene
count from raw sequencing reads remains the one of the most time-consuming steps with
existing tools. Current pipelines do not balance the efficiency and accuracy in large-scale
gene count summarization in both bulk and scRNA-seq experiments. In the third project,
we developed a light-weight k-mer based gene counting algorithm, FastCount, to
accurately and efficiently quantify gene-level abundance using bulk RNA-seq or UMIbased scRNA-seq data. It achieves at least an order-of-magnitude speed improvement over
the current gold standard pipelines while providing competitive accuracy.
KEYWORDS: Cancer Genomics, Pipeline Framework; Somatic Mutation, Driver
Mutations, Single Cell RNA-seq Quantification
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CHAPTER 1. INTRODUCTION
1.1

Cancer Biology
The human body is made of approximately 40 trillion cells (Bianconi et al., 2013).

Norm cells live harmoniously to form the basic units of life and together to form more
complex tissues and organs. The functions of a cell are determined by the genetic material
hosted within the cell in structures called chromosomes. Genes are contained in
chromosomes that carry hereditary information stored in long strings of DNA bases,
adenine (A), guanine (G), cytosine (C), and thymine (T). The DNA sequence in the gene
precisely determines the unique structure and functions of each type of protein in the cell:
DNA sequences are copied into RNA in a process called transcription; a gene that is
transcribed is said to be actively expressed. The transcription of a gene yields an RNA
molecule. And the base sequences in the RNA molecule are translated to synthesize
protein. There are over 30,000 genes in the human genome. However, not all genes in a
cell are expressed and translated into proteins. The expression of different combination of
genes within individual cells creates structurally and functionally diverse cell types.
Therefore, both DNA sequences and gene expression patterns control the protein synthesis
which in turn determines the phenotypes of the cell.
1.1.1

Cancer Genome
Cancer arises as a result of genomic changes that have occurred in a cell. Similar

to normal body cells, a cancer cell carries a copy of the genome from its progenitor
fertilized egg. However, cancer cells acquire a set of different DNA sequences from the
normal cell genome, called somatic mutations. They occur as a consequence of errors when
cells divide or exposure to carcinogenic substances that damage DNA, such as certain
1

chemicals in tobacco smoke, radiation or ultraviolet rays from the sun. Somatic mutations
may have several types of DNA sequence changes: 1) point mutations are single nucleotide
variations (SNVs) affecting only one base of the gene; 2) insertions or deletions (INDELs)
of segments of DNA; 3) copy number alterations (CNAs) are the loss or gain of genetic
material from around 1000 bases of a chromosome to the whole chromosome; 4)
chromosome rearrangements when a piece of a chromosome breaks and attacheds to
another chromosome. These mutations affect the structure, function, and formation of the
corresponding proteins. The abnormal proteins change the behavior of normal cells that
cause healthy cells to become cancerous. For example, it iswell known that the p53 tumor
suppressor gene is a major guardian of the cancer cell (Petitjean, Achatz, Borresen-Dale,
Hainaut, & Olivier, 2007). p53 works actively in normal cell to prevent uncontrolled cell
growth. But some types of mutations in the TP53 gene give rise to mutant p53 proteins that
lose the tumor suppressive function. Cancerous cells take the advantage of the
compromised protein function becoming more invasive, metastatic and resistant.
1.1.2

Tumor heterogeneity
The somatic mutations found in the genome of a cancer cell are the result of

continuous acquisition of mutations and nature selection of cells with growth advantage
during the lifetime of cancer development, analogous to Darwinian evolution framework.
In cancer genomics, a clone is defined as a group of cells from the same ancestral cell. As
a nonmalignant cell evolves to a malignant one through the continuous and random
accumulation of genetic alterations, the stochastic nature of this process results in clones
of cells with diverse phenotypes. Some of the changes are neutral rendering no
consequences to the cells, while some may give rise to cell clones with different properties.

2

For example, a clone carrying errant mutations may activate growth factor signaling to
promote survival or proliferation. Such clone can outgrow other surrounding cells causing
the increase of the clone population. On the other hand, a clone with senescence signaling
might be taken over by other clones leading to the declined or loss of the clone. Therefore,
tumors are evolving overtime and space and composed of distinct cell clones, known as
tumor heterogeneity (Burrell, McGranahan, Bartek, & Swanton, 2013). Tumor
heterogeneity is one of the largest challenges in the cancer therapy development. Although
there are many FDA approved cancer therapies, as well as the ones in clinical trials, there
is no single drug likely to be effective for any cancer types. In many cases, a cancer initially
responses to a therapy but acquires drug resistance clones over time leading to cancer
relapse. Therefore, understanding the tumor heterogeneity is important in cancer research
to overcome drug resistance and develop personalized medicine.
1.2

Next-generation sequencing
The rapid development in Next-generation sequencing (NGS) technology allows

cancer research to comprehensively characterize the cancer somatic mutations and tumor
heterogeneity with less cost. Traditional sequencing techniques such as the single-gene or
array-based methods only allow the genomic exploration of limited targets in lowthroughput fashion (Meyerson, Gabriel, & Getz, 2010). For example, Sanger sequencing
only sequences a single DNA fragment at a time. Researchers are limited to sequence small
stretches of genomic DNA for a small number of samples due to the high cost and low
throughput. NGS technique enables massive parallel sequencing of millions of DNA
fragments providing a cost-effective way to screening genetic variants on thousands of
gene with higher sensitivity, discovery power and sample throughput.

3

NGS DNA and RNA Sequencing technologies are complementary to each other in
cancer research. Genetic mutations in cancer genome can be detected directly at DNAlevel with DNA sequencing. Since mutations on DNA-level have consequences on RNA
transcription, gene expression analysis using RNA sequencing technique is often used to
predict the functionality of genetic changes.
1.2.1

DNA Sequencing
The goal of DNA sequencing (DNA-seq) is to identify genetic irregularities on the

genome, such as somatic SNVs, insertions, deletion, CNAs and structure rearrangement,
that drive the growth of cancers.
Depending on the sequencing library preparation procedures, DNA sequencing can
be applied to the whole genome sequencing (WGS), whole exome sequencing (WES) and
pre-selected regions of interests (gene panels). WGS provides the information of nearly
complete DNA sequences of the genome (achieving around 95%-98% (Kamps et al.,
2017)). WES requires a library enrichment step for all exons. It offers a cost-effective way
to survey all the protein-coding regions of the genome (known as the exome) which covers
about 1% regions of WGS.
WGS and WES platforms have been implemented in many large well-known
national and international collaborations for the comprehensive characterization of the
genomic landscape of human cancer. The Cancer Genome Atlas (Cancer Genome Atlas
Research, 2013) (TCGA) has analyzed over 11,000 individuals representing 33 different
types of cancers revealing common and cancer-specific somatic mutations and signaling
pathways. International Cancer Genome Consortium(International Cancer Genome et al.,
2010) (ICGC) have collected and analyzed cancer samples globally, spanning over 76
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projects. Such sequencing efforts have revealed genetic aberrations that promote tumor
initiation, development, and metastasis, which has substantially advanced our knowledge
in cancer biology. However, DNA-seq is limited in accessing the gene expression to
evaluate the potential functional changes.
1.2.2

RNA Sequencing
RNA-seq addresses the limitation of DNA-seq on the transcriptome level. The

conventional bulk RNA-seq, and most recently, single-cell RNA-seq (scRNA-seq) are used
for sample level and cellular level gene expression profiling. The bulk RNA-seq measures
the gene expression levels from the bulk population of millions of input cells. The resulting
expression value for each gene is the average of all the input cells. It is often used in the
comparative transcriptomics to measure the global gene expression changes under different
conditions. The expression results can then be used for downstream analysis, such as cancer
subtype classification or identifying significantly changed cancer pathways. However,
there are also important biological questions that bulk RNA-seq is insufficient to answer.
Cancer cells are composed of many distinct cell types and clones. It is hard to differentiate
whether the gene expression changes are due to the cellular composition of the tumor
sample or due to the underlying phenotype changes based on bulk RNA-seq. In these
settings, scRNA-seq quantifying the gene expression at the single-cell level provides highresolution profiling for cancer studies. It has been increasingly used to discover new types
and states of cells, and analyze the evolutionary patterns and resulting heterogeneity in
cancer.
The conventional RNA-seq technology has been developed more than a decade.
The standard workflow begins with library preparation including RNA extraction, mRNA
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enrichment, rRNA depletion and complimentary DNA (cDNA) synthesis, followed by
NGS sequencing. It captures the expression levels of thousands of genes at once with high
accuracy. Since RNA is extracted from groups of millions of cells, this technology is also
known as bulk RNA-seq. Bulk RNA-seq measures the average expression level for each
gene across all the cells. They provide vast amount of information for comparing gene
expression differences in multiple conditions, e.g., tumor vs normal tissues, treated vs nontreated response as well as identifying cancer biomarkers. Bulk RNA-seq design assumes
that cells for a given tissue in question are homogenous and gene expression averages
across a pool of cells. This process ignores cell-to-cell variability and drops cell-level
information which makes it insufficient for studying the heterogeneous tumor cell system.
In recent years, technical advancement in NGS and cell separation methods has
made the gene expression profiling at cellular level possible using single cell RNA-seq
(scRNA-seq). Several modern scRNA-seq platforms have been developed, such as 10X
Chromium, DropSeq and Fluidigm C1, capable of profiling hundreds to thousands of
individual cells at once. Those methods use Unique Molecular Identifiers (UMIs) and cell
barcodes and have been optimized for single cell expression profiling with low starting
amounts of RNA. One of the key steps in scRNA-seq is cell isolation where cells can be
physically separated using fluorescence-activated cell sorting (FACS) or they can be
trapped inside hydrogel droplets. Next, within each isolated cell, RNA molecules are
extracted and tagged with UMIs and Cell barcodes. Then cells break to release the mRNAs
for pooled PCR amplification and sequencing. The UMIs and Cell barcodes are important
single cell specific information used in the data analysis. Each mRNA within a cell is
tagged with a cell barcode. A cell barcode is unique to each cell, it tells which cell the
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mRNA is from. In order to trace the cellular origin, each cDNA molecule from the same
cell is labeled with a cell barcode, which is an oligonucleotide sequence unique to the cell,
before pooled library preparation. This allows early pooling of thousands of samples and
increases the sequencing throughput and allow to computationally recover the mRNAs for
a specific cell after the pooled PCR amplification step. Moreover, due to the small amount
of starting material in each cell, scRNA-seq requires a PCR amplification step for cDNAs.
This procedure increases the sensitivity of the scRNA-seq, but on the other hand, PCR
duplicates can not be identified simply based on the reads mapping position. By tagging
the cDNAs with UMIs, sequences with the same UMI can be detected as PCR duplicates.
Therefore, by adding UMIs and cell barcodes in scRNA-seq library preparation, PCR
duplicates and cell origins can be computationally identified enabling sensitively measure
the cellular-level expression differences.
1.3

Current Computational Methods for Cancer Genomics Data Analysis
Cancer genomics is a new research area that applies the rapid technological

development NGS technology to identify the somatic mutations, cancer driver genes,
understand cancer biology and find new methods for cancer diagnosis and treatment. NGS
allows researchers to interrogate the cancer genome in great resolution, high accuracy and
low costs. In the past decade, many NGS approaches have been developed for cancer study
to solve the puzzles in DNA and RNA levels. Parallel with the rapid advancement in NGS
technologies is the development of novel algorithms for NGS data analysis.
1.3.1

Somatic mutations analysis
Identifying somatic mutations is the key step in cancer genomics for the

characterization of a cancer genome. Majority of the somatic mutation calling protocols
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require sequencing of matched tumor and normal samples from the same cancer patient
using WES or WGS sequencing technique. Somatic mutation calling consists of mainly
four components: read preprocessing, variant calling, variant filtering and variant
annotation.
Before mutation calling, the resulting FASTQ files are preprocessed to generate
high quality analysis-ready Binary Sequence Alignment Map (BAM) file. The quality
control (QC) step is performed on the raw FASTQ files to remove poor quality bases and
non-biological sequences (not originated from the sample). Reads passing the QC are
mapped to a reference genome using read alignment algorithms. PCR duplication, which
are reads originating from the same fragment of DNA, can then be detected based on the
alignment position in the BAM file. Reads are ranked by their base-quality scores to
determine the primary and duplicate reads. Duplicate reads are marked with the
hexadecimal value of 0x0400 in the BAM file and will not be included in the variant calling
algorithms. The BAM files from the matched tumor and normal samples are subjected to
local realignment around insertions and deletions to correct mapping errors resulted from
the read aligner and the regions contain INDELs. Since many variant calling algorithms
rely heavily on the per base quality score reported by the sequencer in the BAM files, base
quality score recalibration is required to correct the over- or under-estimated base quality
due to various sequencing technical errors from the sequencer. Pre-processed BAM files
are passed to somatic variant calling algorithm for somatic mutation detection. There are
various tools publicly available covering a wide spectrum of application in somatic point
mutations, INDELs and CNAs calling. Post-filtering of candidate somatic mutations is
often required to reduce false positive calls generated due to the NGS artifacts, read
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alignment errors and low-quality samples. For example, reads generated by the Illumina
platform are commonly affected by the strand bias artifacts, where the heterozygous
genotype can only be observed on one specific strand (Guo et al., 2012). Many variant
calling pipelines compute strand bias scores and use it as a filter to improve the specificity.
1.3.2

Driver mutations
Somatic mutation analysis pipeline for WES/WGS on an individual cancer reveals

hundreds to thousands of somatic mutations present in the cancer genome. One of the major
challenges is to prioritize those somatic mutations to identify the ones casually implicated
in cancer. These mutations, known as driver mutations, contribute growth advantage in
cancer initiation and development, turning on specific pathways promoting cancer.
Deciphering driver mutations is the key to design rational therapeutics aimed at specific
cancer phenotypes, predict patient response to traditional treatments, and expanding the
pool of patients likely to benefit from existing treatments. However, beside the driver
mutations, there are a larger fraction of somatic mutations that do not involve in the
development of cancer. These non-functional mutations, often known as passenger
mutations, happen randomly in cancer cells that have already acquired driver mutations in
the cancer genome. They will be passed to descendants during the cancer cell divisions and
present in the final cancer cells. Therefore, differentiating the driver mutations from
passenger mutations is the main goal for many cancer studies. Despite a few exceptions,
most driver mutations occur in only a small fraction of tumor samples. Therefore,
identifying these low recurrent driver mutations that are buried among a vast pool of
passenger mutations is challenging.

9

1.3.3

RNA-seq Analysis
Analyzing RNA-seq reads to quantify expression at each gene locus is the first step

towards any downstream biological interpretation. There are two popular gene expression
estimation approaches for bulk RNA-seq: gene count and transcript abundance. Gene count
is essentially the total number of reads sequenced within a gene. Many popular statistical
differential expression methods such as DESeq2 (Love, Huber, & Anders, 2014) and edgeR
(Robinson, McCarthy, & Smyth, 2010) take gene count as input. They model it as negative
bionomial distribution to deal with biological variability and overdispersion and
determines differential expression using exact tests (Seyednasrollah, Laiho, & Elo, 2015).
Several tools such as featureCounts (Liao, Smyth, & Shi, 2014) and HTSeq (Anders, Pyl,
& Huber, 2015) are used to obtain the gene counts. These tools require several
preprocessing steps on the raw FASTQ file from the sequencing before performing read
counts: 1) generally, a read trimming step is necessary to remove adapter sequences and
low-quality bases from the FASTQ files (Bolger, Lohse, & Usadel, 2014; Martin, 2011a).
This improves the mappability of the reads during the downstream alignment step. The
quality trimming criteria, such as minimum base quality score or the number of bases to be
trimmed on start or end of each read, are selected empirically by the users. 2) trimmed
reads are aligned to either the reference genome or the reference transcriptome using RNAseq mappers, to generate the BAM files. 3) aligned reads in the BAM files are assigned to
genes based on the genomic locations provided in the Gene Annotation File (GTF) for
gene-/transcript-level read counts. Although there are some efficient algorithms available
to summarize read counts from the BAM file, read alignment is computationally heavy,
requiring large memory and CPU time. Alternatively, read counts can be estimated from
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transcript abundance, by first assigning reads to transcripts using transcript-level
annotation, and summarizing read counts at transcript-level. The gene-level expression can
then be estimated using tools specially designed for summarizing the transcripts counts to
gene counts correcting effective gene length differences across samples (Soneson, Love,
& Robinson, 2015).
The scRNA-seq gene expression analysis can safely borrow the tools and pipelines
that have been developed for bulk RNA-seq. Similar to bulk RNA-seq, reads are first
aligned to the reference genome/transcriptome, and then assigned to genes or transcripts
depending on the selected algorithms. However, after the read assignment, there are
additional single-cell specific steps required for carefully analyzing the data. By
introducing UMIs for each cDNA molecule, reads originated from the same molecule will
have the same UMI sequence, allowing computationally deduplicate reads to reduce the
amplification bias. So instead of counting the number of reads assigned to each gene,
scRNA-seq aims at counting the number of unique UMIs. The UMI collapsing procedure,
in which reads assigned to the same gene with identical UMIs are only counted once, is
performed. However, the UMI counts are often overestimated due to the sequencing/PCR
errors within the UMI sequences. Therefore, error correction for UMIs is necessary before
collapsing reads to UMIs. Another aspect that complicates the analysis is cell barcoding.
cDNAs from the same cell are tagged with a cell-specific sequence, cell barcode, to identify
cells and at the same time, allow the sequencing of thousands of cells in a single run.
Sequencing errors on the cell barcodes not only overestimates the actual number of cells
in the sample, but also may underestimate the UMI counts for the affected cell. Current
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analysis pipelines will filter the low sequencing quality barcodes and barcodes with low
read count to reduce such errors in the downstream analysis.
1.4

Contribution
The aims of the dissertation are to develop novel bioinformatics methods for

resolving several challenges in large-scale cancer genomics study covering sample-level
gene mutation analysis and single-cell level gene transcriptome analysis. We assess the
performance of methods in the completed projects and demonstrate their application in
cancer genomics research.
High-throughput, robust and reproducible Bioinformatics framework for
somatic mutation calling. We developed user-friendly Snakepipe framework for
systematically processing the raw whole -exome/-genome sequencing data for
somatic/germline mutation detection. Snakepipe abstracts the complexity of the analytical
pipeline, parameters selection and computation environment deployment from the users. It
ships with automated NGS best practices pipelines enabling direct “sequence-to-report”
data transformation and requires minimun user configurations. All the analytical softwares
are precompiled and packaged into Docker containers allowing cross-platform pipeline
execution and built-in version controls for reproducibility. Snakepipe scales well to cloud
and HPC infrastrutture for processing large-scale genomics data using distributed
computation resources and parallel computing. Snakepipe provides automatic failure
recovery in cases of unplanned hardware errors or system downtime. Moreover, new
analytical modules can be easily developed and integrated to the existing pipelines.
Efficent mututally exclusive testing for genome-wide drive mutation detection.
We developed MEScan, one of the first tools to allow de novo screening of mutually
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exclusive patterns at the genome scale. The core component of MEScan is a test statistic
directly quantifies the discrepancy between the observed level of mutual exclusivity and
the expected value due to the background, taking into accout for the backgroud mutation
rate heterogeneity and unbalanced mutation patterns. Comparing to other methods,
MEScan offers more power in detection of true mutually exclusive patterns even under the
conditions with low read coverage and is at least two orders of magnitude faster than the
existing methods. We extend MEScan with Markov chain Monte Carlo (MCMC) algorithm
to efficiently screen for mutually exclusive gene sets at the genome scale with a
summarization procedure to select high-confidence findings. MEScan has been applied to
GBM, BRCA, LUSC, OV and PanCancer to identify cancer-specific driver mutations.
Alignment-free gene count quantification for bulk and single cell RNA-seq.
RNA-seq has been widely used in cancer research for differential gene expression between
samples using bulk RNA-seq and more recently for characterizing differential gene
expression at cellular level and studying tumor heterogeneity using scRNA-seq. Although
many algorithms have been published, they either have high computational costs in terms
of time and resources, or they are designed for transcript-level abudance estimation which
requires additional downstream processing for gene-level abudance conversion. Moreover,
since most scRNA-seq library protocols have strong 5’ or 3’-end bias and are sequenced
with low coverage, assigning reads to transcript-level features in scRNA-seq is much more
difficult than for gene-level. Therefore, we developed a novel alignment-free gene
expression quantification algorithm FastCount that performs gene-level expression
analysis for both bulk and single cell RNA-seq . It avoids the time-consuming base-wise
alignment step and classifies reads to gene using gene-specic k-mer signatures. Comparing
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with other methods, it is over an order-of-magnitude faster than the existing gold standard
algorithms while achieves very competitive accuracy.
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CHAPTER 2. Bioinformatics Framework for Characterization of Squamous Cell Lung
Cancers from Appalachian Kentucky
Comprehensive characterization of cancer genomics relies heavily on the
bioinformatics pipelines to analyze the massive production of genomic, transcriptomic,
epigenomic and proteomic NGS data. Currently pipelines are either not executable crossplatform or not easily customizable to extend for new analysis modules. In this project, we
present an open-source, modular computational framework to perform high-throughput,
robust and reproducible bioinformatics analyses of cancer genomic data. It automates best
practice data analysis pipelines, requires minimum configurations from the users and
provides publication-ready figures. We have applied this framework for the
characterization of squamous cell lung cancers from Appalachian Kentucky using WES
data and have identified distinct genomic landscape and potential therapeutic markers.
2.1

Introduction
NGS has a broad spectrum of applications in cancer genomics, however, the

bioinformatic analysis which involves in the transformation of the raw “ATGC” sequence
to meaningful genomic information such as gene expression abundance or gene mutations
is a non-trivial work. NGS generates millions of DNA sequences for a single sample. The
raw DNA sequences are used as source input for cancer biologist to answer various
biological questions. Bioinformatics pipelines, which consist of a series of computational
software to systematically process the large number of genomic data, have become the
power horse for cancer research. However, most researchers have no capacity to perform
large-scale analyses on the NGS data sets using appropriate tools and pipelines. This has
sparked the need for the development of various analysis pipelines and platforms. In the
past few years, there are a variety of analysis pipelines being published such as Galaxy
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(Goecks,

Nekrutenko,

Taylor,

&

Galaxy,

2010),

bcbio-nextgen

(https://github.com/bcbio/bcbio-nextgen), Taverna (Wolstencroft et al., 2013), Toil
(https://github.com/bd2kgenomics/toil), The Cancer Genomics Cloud (Lau et al., 2017),
DNAnexus (http://dnanexus.com), Firehose (http://firebrowse.org/) and many others. They
differ in the analysis procedures, tools selection, parameter configurations as well as
computational environment. Although current bioinformatics pipeline platforms provide
good support to perform data analyses using the built-in modules, customizing and
extending the pipelines to meet various research requirements are very difficult. Galaxy
(Goecks et al., 2010) platform is a web-based approach that enables researchers with
Internet access to perform genomic data analyses through a web page interface. Galaxy
users can create analysis pipelines using the interactive, graphical editor by simply
connecting software modules pre-wrapped by Galaxy. A similar web-based tool, Taverna,
is a workflow management platform, that allows users to define and execute workflows
from a web portal. Those platforms, though very helpful for scientists without
programming or informatics expertise, have several limitations. For example, users are
limited to the number of tools and analyses collected by the platforms; non-programmer
users must wait for the platform updates to apply new algorithms on their data;
programmatic access to service is not available for advanced users. bcbio-nextgen is a
powerful python toolkit for users with extensive programming knowledge. bcbio-nextgen
optimizes each analytical pipeline and software for improved computational performance
handling job distribution, idempotent processing restarts and safe transactional steps.
However, the pipeline customization and development are challenging and complicated
even for users with programming background. Cloud-based commercial service providers,
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such as The Cancer Genomic Cloud and DNAnexus, offer flexible high-performance
computing resources for large-scale collaborative research national and international wise.
Both web interfaces and programming APIs are available for users for conveniently
submitting and monitoring automated large batch analyses. Users can rent the computing
resources such as virtualized computers, data storage and bandwidth on demand and pay
for the exact resources used. However, the cloud-based service is currently not an option
for small labs or institutes with limited funding resources.
NGS data analysis has been a very active research field. A large number of
bioinformatics tools have been published covering every step in the data analysis pipeline.
Novel algorithms have continuingly been developed to aid in discovery of new findings in
the data, or to improve the performance of existing algorithms. It is challenging for caner
biologists to appreciate all the steps and select appropriate tools necessary to conduct the
data analysis properly. A basic somatic mutation calling pipeline based on WES would
contain as few as 12 steps from raw sequence preprocessing to the final somatic mutation
calling. For each individual step in the pipeline, there are collections of tools specially
designed for accomplishing the data transformation. The number of bioinformatics tools to
choose from can be overwhelming. In the past decades, over 30 somatic SNV callers have
been published by different research groups (C. Xu, 2018). They differ considerably in
terms of the core algorithms, filtering criteria, and output. Samtools (H. Li, 2011) uses
Bayesian approaches to calculate the log-likelihood ratio of tumor and normal samples
having the same genotype. Varscan2 (Koboldt et al., 2012) relies on heuristic approaches
to identify variants with supporting reads meeting certain thresholds. Then it applies
Fisher’s exact test on the contingency table of read counts to isolate somatic variants based
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on the p-value. Samtools and Varscan2 can report both SNVs and INDELs. Varscan2 can
also infer the relative copy number changes in tumor sample by performing pairwise
comparison of the read depth between the tumor and its matched normal samples. Mutect
(Kristian Cibulskis et al., 2013) is based on the Bayesian classifier approach, but instead
of modeling the joint genotypes in the tumor and normal samples, it uses joint allele
frequencies to take into account the presence of heterogenous subclones in the tumor
sample. Therefore, a pipeline that employs the standardized best practices workflows and
analytic tools provide a guide for cancer researchers.
Lastly, analyzing data in large scale and collaborative studies requires a crossplatform, scalable and reproducible pipeline management system. From 2012 to 2017, the
amount of genomic data in the Sequence Read Archive (SRA) has doubled four times.
Such data archives are comprehensive enough to allow researchers to ask and answer a
broad range of sophisticated questions without generating new data. Re-analyzing large
collection of data requires pipelines to be easily adapted on different commercial clouds
such as Google Cloud Platform, Amazon AWS and Microsoft Azure or academic highperformance computing (HPC) clusters. Large collaboration projects and consortiums
require standardized and reproducible pipelines to make sure that each participant will
produce the same outputs given the same input data. ICGC, for example, is a large
collaboration on cancer research. More than 25,000 cancer omics data at the genomic,
epigenomic and transcriptomic levels will be collected and analyzed globally to reveal the
repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define
clinically relevant subtypes for prognosis and therapeutic management, and enable the
development of new cancer therapies (International Cancer Genome et al., 2010).
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Reproducible analyses among the collaborators are non-trival. It requires a standard way
to specify all the pipeline dependencies and execution environments for simplifying
deployment, sharing and reusing of tools between research groups.
Snakepipe provides a user friendly bioinformatics pipeline framework. It ships with
automated NGS best practices pipelines for analysing WES and WGS data for
germline/somatical mutation calling and requires mimimun configurations on the user end.
Snakepipe enables direct “sequence-to-results” transformation. It natually determines the
dependencies and tools for each individual steps and jobs are distributed to the work nodes
for serialized or parallel processing. Once the analyses are complete, Snakepipe
automatically collect the input source files, user configurations and results in a compressed
format for backup and reproducible research collabration. New pipelines and functions can
be easily developed and integerated to the existing ones in the Snakepipe framework by
containerization of bioinformatics tools and job definitions in simple python-like scripts.
The overall workflow for mutation calling is comprised of raw seqeuecning read
preprocessing, mutation calling, significantly mutated genes identification, CNA calling,
cohort comparison, clinical actionable mutation prediction as well as comprehensive
results visualization.
2.2

Pipeline management
The pipeline framework adopts a modern workflow management engine,

Snakemake (Koster & Rahmann, 2018) and docker containers. The Snakemake engine
defines each pipeline in a “Snakefile” using a domain-specific language. It adopts the rule
concept used by the GNU Make (Stallman RM, 1991), with extended functionalities and
flexibilities. The analysis steps of a pipeline are composed of corresponding rule

19

definitions. A regular rule expresses 1) input files 2) output files and 3) a shell command
or scripts using other programming languages (such as Python or R scripts) which describes
how the output files are generated given the input files. In order to naturally represent the
plan of job executions and job dependencies in a workflow, Snakemake uses a directed
acyclic graph (DAG), where a vertex is the execution of a job defined by a rule and a
directed edge indicates the execution sequence of the 2 jobs. A job on the ending vertex of
each edge requires the input from the job on the starting vertex of the edge. Therefore, a
path which is the sequence of edges in the DAG serializes the execution order of the
individual jobs in the workflow. Snakemake has the following properties: i) it
automatically detects the rules required for the completion of the final workflow; ii) jobs
on disjoint paths can be run in parallel; iii) it only executes rules with missing output files
or changes of the input file modification time to avoid re-running the completed jobs and
for failure recovery; and iv) jobs can be executed locally and distributed to accessible
computing resources, such as cloud or HPC.
2.3

Runtime environment deployment
The analytical tools required in the workflow are managed using docker containers

to simplify the deployment of the pipeline under different computing environments, for
version control and research reproducibility. Each program and all its dependencies are
packaged into a docker container tagged with a unique version id. The docker images are
hosted on Docker Hub and can be easily shipped to any machine, either cloud or local.
Setting up the tools from scratch only needs minimal configuration of Docker or
Singularity. Snakepipe will infer the necessary container images based on the types of the
NGS data and automatically pulls the images from the Docker Hub. The pipeline is portable
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and robust that enables reproducibility, transparency and shareability. It can be easily
deployed and executed cross-platform such as local workstations, HPC and cloud
platforms.
2.4

Best practice workflows
Snakepipe WES/WGS data analysis pipeline for germline/somatic mutation calling

(Error! Reference source not found.) is developed based on the recommended best
practice from Broad Institute using the Genome Analysis Toolkit (Aaron McKenna et al.,
2010) (GATK). Sequencing reads were trimmed and filtered using Cutadapt (v1.4.1)
(Martin, 2011b), then aligned to human reference genome b37/hg19 using BWA (v.0.7.9a)
(H.

Li

&

Durbin,

2010).

PCR

duplicates

were

removed

using

Picard

(http://broadinstitute.github.io/picard/, v1.115). The Genome Analysis Toolkit (GATK
v3.1-1) (A. McKenna et al., 2010) was used for local indels realignment and base quality
recalibration. Somatic point mutations and indels were detected using MuTect (v1.1.4) (K.
Cibulskis et al., 2013) and SomaticIndelDetector (GATK v2.3-9), respectively, with
default settings. Mutations were annotated using Oncotator (v1.4.1.0) (Ramos et al., 2015).
Significantly mutated genes were identified using MutSigCV (v1.4) (Michael S. Lawrence
et al., 2013). Somatic copy-number alterations (SCNA) analysis was conducted using
ExomeCNV (Sathirapongsasuti et al., 2011), an R statistical package. Exonic CNAs were
inferred based on the depth-of-coverage ratio between matched tumor and normal samples.
Then, CNAs calls were combined into larger segments using circular binary segmentation
in DNAcopy (Venkatraman E. Seshan). Gistic2.0 (Mermel et al., 2011) with a confidence
level of 0.95 was used on the copy ratio profiles to identify significantly amplified/deleted
regions. To evaluate the clinical relevance of the somatic genomic alterations identified in
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our cohort, we downloaded the OncoKB database (Chakravarty et al., 2017) (accessed in
December 2017) to identify FDA approved drugs for the FDA-recognized and standard
care biomarkers.

Figure 1 Whole exome sequencing data analysis pipeline for somatic mutation calling and
copy number variation detection. The pipeline contains two major parts: 1) preprocessing
to prepare analysis-ready bam files from tumor and matched normal samples; 2) variant
calling step.
2.5

Results
We applied the Snakepipe to analyze the WES of 51 SQCC patients from AppKY,

which includes an overview of somatic alterations and copy-number variations, explores
unique mutational patterns, and provides a clinically actionable assessment of mutations in
this population. Essential to this effort was the full sharing of the comprehensive genomic
profile of lung SQCC in TCGA (The Cancer Genome Atlas Research Network, 2012),
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which provided the comparison of the initial 178 subjects from a US genomic profile that
does not focus on Central Appalachians.
2.5.1

Overview of somatic alterations
The mean coverage of WES across the targeted regions was 104× with 92% of

targeted bases being covered at ≥ 30×. Raw sequencing data are available at dbGaP
(Accession: phs001651.v1.p1). We identified 16,005 somatic single-nucleotide variants
and 217 somatic insertions or deletions (indels) across 51 matched tumor and normal pairs
in the protein coding regions. Of those mutations, 12,117 were predicted to be non-silent
mutations resulting in an amino acid change. The mean mutation rate in our cohort was
237 non-silent mutations per patient, corresponding to 8.5 mutations per megabases (Mb).
Among non-silent mutations, transitions and transversions at CpG sites were the most
commonly observed mutation types, with rates of 11.5 per Mb and 15.5 per Mb,
respectively. For non-CpG sites, transitions were more frequently observed at C:G sites
(3.2 per Mb) than at A:T sites (1.8 per Mb). Similarly, transversions were more frequently
observed at C:G sites (8.0 per Mb) than at A:T sites (2.0 per Mb).
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Figure 2. Significantly mutated genes in lung SQCC. Significantly mutated genes
(FDR<0.2) from whole-exome sequencing of 51 samples from Appalachian Kentucky
patients.The number and percentage of samples with mutations in each gene are shown on
the left. Samples are displayed as columns, with the overall number of mutations, smoking
status, and tumor stage plotted at the top.

2.5.2

Significantly mutated genes
We identified 3 genes that were significantly mutated (i.e., non-silent mutation rates

higher than background mutation rates) in the AppKY cohort with an FDR < 0.2 using
MutSigCV (Michael S. Lawrence et al., 2013): TP53, PCMTD1 and IDH1. To increase the
statistical power of our analysis, we followed the approach of the TCGA SQCC report
(2012) and performed a secondary MutSigCV (M. S. Lawrence et al., 2013; Michael S.
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Lawrence et al., 2013) analysis to only consider genes causally implicated in cancer
according to the COSMIC database (Futreal et al., 2004). This approach enabled us to
identify 11 additional genes that were significantly mutated with an FDR < 0.2: PIK3CA,
RNF43, MLLT10, STK11, NFE2L2, DEK, POT1, ATP2B3, HRAS, HOXA11 and HOXA13
(Figure 2).

Figure 3 GISTIC amplification (left) and deletion (right) plots of the G-scores (shown at
the top of the figure) and q-values (shown at the bottom of the figure) across the entire
region analyzed.
2.5.3

Copy number variation analysis
SCNAs were analyzed using WES data. We identified regions with significant

SCNAs using Gistic2.0 (Mermel et al., 2011). There were 18 peaks of significant
amplification and 34 peaks of significant deletions (FDR<0.25). Significantly amplified
regions were 3q27 (MCF2L2), 8p11 (FGFR1, TACC1, WHSC1L1, LETM2, RNF5P1),
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11q13 (CCND1-oncogene), 7q21.2 (CDK6), 19q13, 13q34, 5p15, 8q24 (MYC-oncogene)
and deleted regions were 9p21 (CDKN2A-tumor suppressor, CDKN2B), 8p23, 10q23
(PTEN, CFL1P1, KLLN), 17p13, 4q28.2 (VEGFC), 22q13.2 (CHEK2). Consistent
amplification patterns were seen in certain related sets of genes, such as stem cell renewal
genes.
2.5.4

Comparative mutational analysis with other cohorts
We first compared somatic mutations and SCNAs of AppKY lung SQCC to TCGA

cohort (Campbell et al., 2016; Kim et al., 2014; C. Li et al., 2015; The Cancer Genome
Atlas Research Network, 2012). We focused our comparison on significantly mutated
genes in at least one cohort by the MutSigCV (M. S. Lawrence et al., 2013) analysis. Our
comparative analysis presented here (Table 1) included somatic mutations (point mutations
and indels) only in the calculation of gene alteration rate. Both cohorts showed similar rates
of alterations for TP53 (68.6% AppKY, 80.9% TCGA, FDR q-value=1.000), PIK3CA
(11.8% AppKY, 15.7% TCGA, FDR q-value=1.000), NOTCH1 (11.8% AppKY, 8.4%
TCGA, FDR q-value=1.000) and PTEN (5.9% AppKY, 7.9% TCGA, FDR qvalue=1.000).
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Table 1. Somatic alteration rate comparison between AppKY and TCGA of Lung SQCC.
The comparison focuses on genes that were identified as significantly mutated based on
the MutSigCV analysis in at least one of the two cohorts.
AppKY (%) TCGA (%) p-value§
Hugo Symbol*
q-value¥
K
IDH1○
11.80%
1.10%
0.002
0.039
K
PCMTD1○
17.60%
3.90%
0.002
0.045
DEK
5.90%
0.00%
0.011
0.200
NFE2L2⊕
3.90%
15.20%
0.032
0.584
T
CDKN2A○
3.90%
14.60%
0.050
0.830
HOXA11
3.90%
0.00%
0.049
0.830
TP53⊕
68.60%
80.90%
0.082
1.000
T
PTEN○
5.90%
7.90%
0.770
1.000
PIK3CA⊕
11.80%
15.70%
0.655
1.000
T
KEAP1○
9.80%
12.40%
0.806
1.000
T
KMT2D○
9.80%
19.70%
0.142
1.000
T
HLA-A○
7.80%
3.40%
0.236
1.000
T
NOTCH1○
11.80%
8.40%
0.424
1.000
T
RB1○
2.00%
6.70%
0.307
1.000
RNF43
5.90%
1.70%
0.126
1.000
MLLT10
7.80%
3.90%
0.269
1.000
STK11
3.90%
1.70%
0.309
1.000
POT1
5.90%
2.20%
0.186
1.000
ATP2B3
3.90%
2.20%
0.617
1.000
HRAS
5.90%
2.80%
0.381
1.000
HOXA13
3.90%
0.60%
0.125
1.000
K : significantly mutated in AppKY only; ○
T : significantly mutated
*○
in TCGA only; ⊕: significantly mutated in both cohorts
§
The p-value was based on the Fisher’s exact test to compare
percentages of samples that had somatic alterations (somatic mutations
or SCNAs) in the two cohorts.
¥
The q-value was based on the Benjamini–Hochberg procedure.
Genes with significant differences (FDR<0.2) in the alteration rate are
shown in bold.
Significant differences in mutation rates between the AppKY and TCGA cohorts
were observed. The IDH1 mutations were observed in 11.8% of patients in the AppKY
cohort. In contrast, only 1.1% of patients in the TCGA cohort had IDH1 mutations (FDR
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q-value=0.039). Similarly, the AppKY cohort also showed a higher rate of mutations in
PCMTD1 (17.6% AppKY vs. 3.9% TCGA, FDR q-value=0.045). Even after adjusting for
age, gender, stage, and smoking via exact logistic regression, mutation frequencies are still
significantly different between the AppKY and TCGA cohorts for IDH1 (p-value=0.0024)
and PCMTD1 (p-value=0.019).
2.5.5

Clinically actionable mutations assessment
We investigated the somatic mutations/SCNAs observed in our cohort in

association with FDA approved agents or published or ongoing clinical trials for nonsmall-cell lung carcinoma (NSCLC) or other tumor types. 5 subjects (10%) had actionable
mutations, defined as FDA approved drugs (either for this indication or another cancer
type), with a total of 8 somatic mutations/SCNAs events found in these 5 individuals.
Additionally, we found that 33 out of 51 subjects (65%) had high (>20 mut/MB) or
intermediate (6-20 mut/MB) tumor mutation burden (TMB), indicating an additional group
of therapeutic choices for this population using checkpoint inhibitors. Overall, 65% of
subjects had actionable mutations with FDA approved drugs and/or TMB that was high or
intermediate. Many others had mutations that are under clinical investigation (Table 2).
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Table 2. Clinically actionable mutations identified for APPKY patients.
Gene

Patient

Mutation

ERBB2

MCC-51

Amplification

KIT

MCC-12

Amplification

KIT

MCC-36

Amplification

KIT

MCC-47

Amplification

PDGFRA
PDGFRA
PDGFRA
TSC2
HRAS

MCC-12
MCC-36
MCC-47
MCC-7
MCC-7

Amplification
Amplification
Amplification
Deletion
c.181C>A

NF1

MCC-2

c.55G>T

HRAS
BRAF

MCC-12
MCC-19

c.34G>A
c.1391G>T

KRAS

MCC-25

c.40G>A

PTEN
HRAS
NOTCH1
NOTCH1
HRAS

MCC-47
MCC-49
MCC-21
MCC-29
MCC-49

c.367C>T
c.37G>C
Deletion
Deletion
Amplification

KRAS

MCC-37

Amplification

PTEN

MCC-2

Deletion

KRAS

MCC-12

Amplification

KRAS

MCC-10

Amplification

HRAS

MCC-40

Amplification

Drug
Trastuzumab;Neratinib;
Lapatinib + Trastuzumab,
Pertuzumab + Trastuzumab,
Ado-trastuzumab emtansine,
Lapatinib, Trastuzumab
Imatinib;Sunitinib, Sorafenib;
Regorafenib, Imatinib,
Sunitinib
Imatinib;Sunitinib, Sorafenib;
Regorafenib, Imatinib,
Sunitinib
Imatinib;Sunitinib, Sorafenib;
Regorafenib, Imatinib,
Sunitinib
Imatinib
Imatinib
Imatinib
Everolimus
Tipifarnib
LTT462, Binimetinib,
BVD523, Trametinib
Tipifarnib
LTT462, BVD-523, KO-947
LY3214996, KO-947, GDC0994;
Binimetinib, Trametinib
GSK2636771, AZD8186
Tipifarnib
PF-03084014
PF-03084014
Tipifarnib
LY3214996, KO-947, GDC0994;
Binimetinib, Trametinib
GSK2636771, AZD8186
LY3214996, KO-947, GDC0994;
Binimetinib, Trametinib
LY3214996, KO-947, GDC0994;
Binimetinib, Trametinib
Tipifarnib
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DrugLevel
1;3A;1

2A;2A;1
2A;2A;1
2A;2A;1
2A
2A
2A
2A
4
4
4
4
4;4
4
4
4
4
4
4;4
4
4;4
4;4
4

PTEN
MCC-9
Deletion
GSK2636771, AZD8186
BRAF
MCC-19
Amplification
LTT462, BVD-523, KO-947
PTEN
MCC-33
Deletion
GSK2636771, AZD8186
Note: The drug level is defined by OncoKB. Levels 1 and 2 are FDA approved drugs.
2.5.6

4
4
4

Prediction of the effect of IDH1 mutations

Figure 4. IDH1 and PCMTD1 mutations. (A) IDH1 mutations and their mutation
frequencies (circles). (B) PCMTD1 mutations and their frequencies (circles).

Mutations in IDH1 and its homolog IDH2 coding for cytosolic and mitochondrial
isocitrate dehydrogenases, correspondingly, are common in gliomas (Yan et al., 2009) and
myeloid neoplasms (Molenaar et al., 2015), but rare in lung cancer. We observed multiple
IDH1 variants: R132H, V178A, A307S and L352P (Figure 4A), and the R132H variant
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was confirmed by immunohistochemistry. The IDH1 variant R132H is reported in a variety
of cancers and the role of various R132 missense substitutions has been studied
extensively. These mutations are generally heterozygous, suggesting a gain-of-function by
the enzyme, and supported by mechanistic studies demonstrating that the R132H variant
protein has an aberrant enzymatic activity, converting α-ketoglutarate (2OG) to (R)-2hydroxyglutarate (2HG) (Dang et al., 2009). This enantiomer of 2HG acts as an
oncometabolite and interferes with cell differentiation (Lu et al., 2012).
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Figure 5. Functional analysis of IDH1 variants. (A) Segments of multiple sequence
alignment for representative IDH1 (upper set) and IDH2 (lower set) orthologs, showing
conservation of Arg132, Val178, Ala207, and Leu352. Numbers are provided for a human
IDH1 protein. A complete alignment and sequence accession numbers are shown in Figure
7. Positions 132, 178, 307, and 352 are marked and highlighted in yellow, whereas
substitutions in these positions are highlighted in blue. For all other positions, residues that
are identical to those in the human IDH1 are highlighted in gray. Human, Homo sapiens;
Frog, Xenopus tropicalis; Fish, Takifugu rubripes; Nematode, Caenorhabditis elegans,
Worm, Saccoglossus kowalevskii; Lancelet, Branchiostoma floridae. (B) Effect of IDH1
variants on enzyme activity. Left: effect of R132H and A307S mutants; Right: effect of
V178A and L352P mutants. The two-sample t-test was performed to compare each IDH1
mutant versus the wild type and the Bonferroni correction was used for multiple
comparison adjustment. • Statistically significant reductions of NADPH production
comparing IDH1 R132H versus wild type; ♦Statistically significant reductions of NADPH
production comparing IDH1 L352P versus wild type.
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To understand potential consequences of the other detected IDH1 variants (V178A,
A307S, and L352P), we applied a recently developed evolutionary approach (Adebali,
Reznik, Ory, & Zhulin, 2016), based on the principle that most deleterious, and hence
potentially disease-promoting mutations, result in reduced evolutionary fitness and thus are
selected against during evolution. Homologous genes derive from a common ancestor
gene, while orthologous genes diverge after a speciation event in two different species;
paralogous genes occur within a single species and diverge after a duplication event. Unlike
orthologous genes, a paralogous gene evolves new function(s), making the distinction
between the roles of orthologous and paralogous genes in disease critical for estimating
disease risk using molecular conservation (Adebali et al., 2016). We have identified both
IDH1 and IDH2 orthologs in representative genomes from all major eukaryotic
supergroups and built a maximum-likelihood phylogenetic tree (Figure 6) from their
multiple sequence alignment (Figure 7). Satisfactorily, we found that position
corresponding to R132 in the human IDH1 protein is absolutely invariant, not only in
orthologous sequences, but in all IDH homologs (Figure 6), which is consistent with
deleterious effects of its substitution. Similar to R132, both A307 and L352 are also
invariant residues in all IDH1 and IDH2 orthologs and all other IDH1 homologs with
uncertain evolutionary history from all major eukaryotic supergroups (Figure 5A and
Figure 7). Because no substitutions in these positions occurred since the last eukaryotic
common ancestor, any changes in these positions were predicted to be disease-promoting.
While position V178 is not invariable among all homologs, the only allowable substitutions
are V178I (occasionally found in both IDH1 and IDH2) and V178C (occasionally found
only in IDH2) (Figure 5A and Figure 7). No V178A substitution was ever detected in any
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IDH homologs, including the most distant ones, and might be cancer-promoting. We
therefore tested the activity of these mutations using an enzymatic activity assay.
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Figure 6. Maximum likelihood phylogenetic tree of IDH1 and IDH2 proteins from a
representative genome set. Clades of definite IDH1 and IDH2 orthologs are highlighted in
green and magenta, correspondingly. Multiple sequence alignment was used to construct
the tree and sequence accession numbers are shown in Figure 7. Human proteins are
marked by a star.
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Figure 7. Multiple sequence alignment of IDH1 and IDH2 proteins from a representative
genome set. Sequence labels and the order of sequences correspond to that of the
phylogenetic tree shown in Figure 6. Positions corresponding to K132, V178, A307, and
L352 in the human IDH1 are highlighted.

To test the function of IDH1 and the effect of different variants on IDH1 functions,
we constructed plasmids with wildtype (WT) IDH1 and mutant IDH1 genes (pcDNA3.136

IDH1-A307S; pcDNA3.1-IDH1-R132H; pcDNA3.1-IDH1-V178A; and pcDNA3.1IDH1-L352P). We tested the enzymatic activity of the WT and each IDH1 variant by
analysis of isocitrate dehydrogenase activity that directly tests NADPH production. We
found that R132H and L352P mutations significant attenuated net NADPH production of
IDH1 (Figure 5B), while A307S and V178 mutations had no significant effect. In the
context of other R132 IDH1 studies, attenuation of net NADPH production by the R132H
variant enzyme implies that production of 2HG in the oncogenic reaction consumes
NADPH. These results suggest that R132H is a point mutation that disables or attenuates
some enzymatic activity of IDH1.

Figure 8. IDH1 mutations and IDH1 associated pathway analysis.
Variant IDH1 may produce the oncometabolite 2HG that inhibits 2OG-dependent
dioxygenases; the 2OG-dependent dioxygenases are highly sensitive to inhibition by 2HG.
Mutations in IDH1 and 2OG dependent enzymes are mutually exclusive. The number and
percentage of samples with mutations in each gene are shown on the left. Samples are
displayed as columns.

As previously mentioned, certain variants of IDH1 are known to produce the
oncometabolite 2HG (Cairns & Mak, 2013; Ward et al., 2012), which showed inhibitory
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effects on 2OG-dependent enzymes, with the histone demethylases (KDM) most sensitive
to inhibition (Joberty et al., 2016). There are two classes of KDMs: 2OG-dependent and
FAD-dependent. The biochemical function of both classes of KDMs is to demethylate
specific lysine residues in histones, leading to regulation of gene expression (Labbe,
Holowatyj, & Yang, 2013). KDMs may also regulate gene expression via demethylation
of other residues on histones (Walport et al., 2016). Based on this information and our
discovery of mutually exclusive mutational patterns between certain histone demethylases
and methyl transferases, we proceeded to ask if mutations in IDH1 share a mutually
exclusive pattern with 2OG-dependent enzymes in this lung SQCC population. We found
that mutations in 2OG-dependent KDMs are mutually exclusive with IDH1 (Figure 8),
suggesting that mutations in either IDH1 or the 2OG-dependent KDMs lead to a common
inhibition of histone demethylation. The mutually exclusive mutational pattern involving
IDH1 is statistically significant (P=0.018 based on the MEGSA (X. Hua et al., 2016)
method). This mutual exclusion is a novel observation in lung SQCC, which has not
previously been reported. More than 35% of AppKY patients have mutations in 2OGdependent protein demethylases, the vast majority of them in KDMs. Furthermore, when
all lysine demethylases are included in the analyses, only one FAD-dependent, KDM1A, is
found to be mutated in one case. These data suggest that IDH1 mutations may regulate
gene expression via inhibition of 2OG-dependent KDMs. We further evaluated the
mutations in the KDMs to see if they had functional consequences and found mutations
possibly affecting a variety of specific regions in each of the different KDMs. The
mutations in the KDMs are not localized to a specific region, are highly dispersive across
each gene, and functionally affect protein-protein interactions, post-translational
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modification sites, and metal-binding, suggesting a general loss-of-function. This loss-offunction interpretation is further strengthened by the fact that IDH1 mutations responsible
for the production of 2HG, which is inhibitory to KDMs (Joberty et al., 2016), are mutually
exclusive with mutations in the above mentioned KDMs (Figure 8). The mutational
patterns observed between IDH1 and KDMs suggest that restoring the KDM 2HGinhibited function in cases with certain IDH1 mutations may prevent cancer signaling
through IDH1 (Mondesir, Willekens, Touat, & de Botton, 2016).
2.5.7

Localization of PCMTD1 mutations
PCMTD1 has an N-terminal canonical iso-aspartate methyl transferase (PCMT)

domain, which in another protein has been shown to methylate iso-aspartate and aspartate
residues on proteins including histone H4, and suggests a role in protein repair or turnover
(Biterge, Richter, Mittler, & Schneider, 2014; McFadden & Clarke, 1982). PCTMD1’s Cterminal domain is not well characterized, and the cellular function(s) of the gene-product
are not known. In the AppKY dataset, mutations in PCMTD1 were always observed in the
C-terminus coding region of the protein and never in the N-terminus region. These results
are similar to other cancer studies including pancreatic cancer, melanoma, aggressive
rhabdomyosarcoma and others (Figure 4B and Table 3). Therefore, the C-terminus coding
region of PCMTD1 appears to be a mutation hotspot.
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Table 3. PCMTD1 mutations. The PCMTD1 mutations reported in the literature are in the
C-terminal SOCS Box. PCMTD1 mutations in cancers are rarely found in the PCMT
domain. The vast majority of mutations (except 1 case in TCGA Lung SQCC and 1 case
in Glioblastoma) occur in the SOCS Box.

Yes
No

No

Yes

No

65%

22622578
22610119
24816255
25855536
24120142

Lung SQCC
Aggressive
Rhabdomyosarcoma
Melanoma
Prostrate
Gastric Carcinoma
Pancreatic Cancer
Glioblastoma

SOCS Box (240-356)
Cul5
BC
Spacer
Box
(~16) (~82)
(~15)
No
Yes
Yes

No
No
No
No
Yes

Yes
No
No
Yes
No

Yes
No
Yes
Yes
Yes

Yes
Yes
No
No
No

28%
1%
7%
7%
1%

AppKY

Lung SQCC

No

No

Yes

Yes

18%

Study
PMID
22960745
24793135

Cancer

PCMT
(1-239)

% of
cases
4%

A recent report indicates that lysine methyltransferases (KMTs), KMT2A and
KMT2D, are upregulated by gain-of-function TP53 mutations (mutations in the DNA
binding domain) (Zhu et al., 2015). PCMTD1 is also a methyltransferase (MT). As
mentioned earlier, isoaspartate residues of TP53 have been shown to be methylated, and
this in turn has been shown to regulate levels of TP53 as well as its function during DNA
damage (Lee et al., 2012). CUL5, a PCMTD1 interacting protein is recruited to target the
TP53 protein for proteasomal degradation (Okumura, Joo-Okumura, Nakatsukasa, &
Kamura, 2016). We explored the connections between PCMTD1 and TP53, the most
frequently mutated gene in the AppKY dataset (69%). TP53 mutations in this cohort
showed a strong signature for a smoking-associated mutational pattern, with frequent
mutations in the protein regions 157-159 and 192-193 (Halvorsen et al., 2016). We also
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found that the mutations within the smoking signature, specifically the 157-159 region
frequently co-occur with mutations in PCMTD1.
2.6

Conclusion
From our analyses and other studies, there is growing evidence that numerous

pathways converge on protein modification enzymes, including MTs and protein
demethylases, that function via direct protein modification, and in the regulation of gene
expression via chromatin modification. Therefore, regulation of protein MTs and
demethylases affects the methylation status of histones and other substrates such as
signaling proteins50. For example, mutations in PI3K/AKT signaling regulate H3K4
methylation through KDM5A (Hamamoto, Saloura, & Nakamura, 2015), and PIK3CA and
AKT phosphorylate KDMs and KMTs, which alters their functions and renders them
oncogenic5 (Hamamoto et al., 2015; K. Xu et al., 2012). Thus, these methyltransferases
and demethylases may be promising targets in cancer therapy.
The observation of a smoking-associated mutational signature in TP53 is not
surprising (Schoenberg, Huang, Seshadri, & Tucker, 2015) given the high rate of smoking
in AppKY, and this signature appears to frequently co-occur with mutations in PCMTD1.
We hypothesize that PCMTD1 could function as a regulator of TP53, although further
study will be needed to examine this hypothesis. In the AppKY population, concentrations
of arsenic, chromium and nickel are higher than the US national levels (Johnson et al.,
2011). The toxicity of carcinogenic metals has been shown to be mediated by altering
histone methylation via 2OG-dependent enzymes (Arita et al., 2012; Chervona, Arita, &
Costa, 2012). In addition to the known link to tobacco exposure, we hypothesize that
environmental exposures relevant to AppKY may be contributing to the development of
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this (R)-2-hydoxyglutarate-specific cancer mechanism in our cohort. This could help
explain the IDH1 and 2OG-dependent KDMs mutually exclusive pattern seen only in the
AppKY cohort.
This study is the first characterization of the genomic alterations in lung SQCC
from AppKY residents. Our data shares several findings with the TCGA, namely high rates
of TP53, NOTCH1, PTEN and PI3KCA, the complexity of genomic patterns, and wellrecognized pathways upregulated in SQCC lung cancer. However, the AppKY SQCC has
a specific genetic signature characterized by an increased number of IDH1 and PCMTD1
mutations, as compared to the TCGA. The findings in this study have important
mechanistic implications for how SQCC lung cancers develop in AppKY residents and
provide insights into treatment. The 10% potentially actionable mutations/SCNAs
observed in our AppKY cohort (based on FDA-approved drugs) coupled with 65% of
subjects with high or intermediate mutation burden indicates that a majority of these
patients have potential molecular targets for treatment including ERBB2 amplification with
FDA approved monoclonal antibodies and tyrosine kinase inhibitors; PDGFRA, and TSC2
where targeted agents are approved in other tumor types; as well as other mutations with
targeted therapies under active investigation (HRAS, KRAS, PTEN, NOTCH1, NF1, BRAF).
The current study adds to the body of literature that supports drug development based on
mutations in lung SQCC and highlights genomic population differences that are relevant.
By utilizing therapies specific to actionable mutations that are common in our AppKY
population, we can provide a more personalized approach through directed drug discovery
targeting highly mutated genes, such as IDH1 and PCMTD1.
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CHAPTER 3. MESCAN: A Powerful Statistical Framework for Genome-Scale Mutual
Exclusivity Analysis of Cancer Mutations
3.1

Introduction
Cancer arises from somatically acquired genetic and epigenetic alterations. While

large consortia like TCGA and ICGC have profiled genomic somatic mutations of
thousands of tumor samples from various cancer types based on whole-genome/-exome
sequencing, meaningful mechanistic interpretation of these gene variation results are still
very limited. One basic yet challenging task is to distinguish driver mutations, which are
causally implicated in cancer development, from passenger mutations, which occur
randomly with neutral effect. Despite a few exceptions, most driver mutations occur in
only a small fraction of tumor samples (Tamborero et al., 2013). Therefore, identifying
these low recurrent driver mutations that are buried among a vast pool of passenger
mutations is challenging. Tremendous efforts have been spent on identifying driver
mutations ((L. Ding et al., 2018); ICGC/TCGA Pan-Cancer Analysis of Whole Genomes
Consortium, 2020). It has been suggested that assessing mutations in a set of related genes
may enhance the power of the detection, since genes act together in various biological
(regulatory, signaling, and metabolic) pathways (Leiserson, Blokh, Sharan, & Raphael,
2013; M. D. M. Leiserson, H.-T. Wu, F. Vandin, & B. J. Raphael, 2015; Szczurek &
Beerenwinkel, 2014; Vandin, Upfal, & Raphael, 2012). Mutations associated with genes
within a pathway often show a mutually exclusive pattern across a cohort of patients,
meaning that each patient carries just one mutation in the pathway, which is often sufficient
to perturb the function of that pathway. Although the mutation rate for each gene in the
pathway is often low, the mutually exclusive mutations among genes in the pathway
provide a stronger combined signal that is easier to detect. This is due to the increased
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mutation rate by considering the set of genes as a whole as well as the mutually exclusive
pattern across genes that provides an additional signal for detection.
Several bioinformatics methods have been developed for de novo discovery of
mutually exclusive gene sets (Constantinescu, Szczurek, Mohammadi, Rahnenfuhrer, &
Beerenwinkel, 2016; Li Ding et al., 2018; Xing Hua et al., 2016; Y.-A. Kim, S. Madan, &
T. M. Przytycka, 2017; Leiserson et al., 2013; M. D. M. Leiserson, M. A. Reyna, & B. J.
Raphael, 2016; M. D. M. Leiserson et al., 2015; Mina et al., 2017; Szczurek &
Beerenwinkel, 2014; Vandin et al., 2012). However, there are still three major challenges.
Firstly, the heterogeneity in background (or passenger) mutation rate needs to be adjusted.
Lawrence et.al (Michael S. Lawrence et al., 2013) demonstrated large variation in the
background mutation rate across genes and across patients of the same cancer type from
TCGA data. Adjusting for a patient- and gene-specific background mutation rate has been
shown as the key to reducing artifactual findings and improving the identification of driver
genes (Korthauer & Kendziorski, 2015; Michael S. Lawrence et al., 2013; Youn & Simon,
2011) . This is also true for dN/dS-style tests, where dS represents a proxy for background
mutation rate (Nik-Zainal et al., 2016; Zhao et al., 2019). The heterogeneity in the
background mutation rate can also affect identification of mutually exclusive mutational
patterns, because spurious patterns are more likely to occur in genes and patients with high
background mutation rates. However, only a few mutual exclusivity analysis methods have
taken into account the heterogeneity in the background mutation rate, and adjustment
approaches are limited. Hua et al. (X. Hua et al., 2016) used a likelihood-based approach
to directly adjust for the background mutation rate. However, the method is based on the
assumption that the relative mutation frequencies of genes in a mutually exclusive gene set
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are proportional to the background mutation frequencies of those genes. It also assumed
the same background mutation rate of a gene across patients. A few other methods (Y. A.
Kim, S. Madan, & T. M. Przytycka, 2017; M. D. Leiserson, M. A. Reyna, & B. J. Raphael,
2016; M. D. Leiserson, H. T. Wu, F. Vandin, & B. J. Raphael, 2015) used a conditional
technique to indirectly adjust for the mutation rate heterogeneity. These methods used
either permutation or a hypergeometric distribution method to make inferences by
conditioning on the observed mutation frequencies of genes and patients. However, the
conditional technique was unable to distinguish whether the observed mutation frequencies
were due to random background noise or true signals that drive cancer development.
Secondly, as pointed out by Leiserson et al. (M. D. Leiserson et al., 2015), a gene
with a very high mutation rate plus a few other genes with very low mutation rates may
show a mutually exclusive mutational pattern by random chance. The highly mutated gene,
e.g. TP53 in several cancer types, could be a driver gene by itself. But other genes in this
spurious mutually exclusive set may not be drivers and may be biologically unrelated to
the highly mutated gene. Therefore, such an unbalanced pattern, which is dominated by the
highly mutated gene, is less of interest as compared to a more balanced pattern, where each
gene in the gene set has a non-negligible contribution to the overall pattern. Note that
adjusting for the background mutation rate does not solve this problem. The highly mutated
gene could be a driver whose mutation rate is much higher than the background so that the
pattern would still be significant even after the background mutation rate adjustment. Many
bioinformatics methods do not distinguish unbalanced and more balanced patterns, and
therefore can lead to spurious results. Although a conditional method (M. D. Leiserson et
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al., 2015) has been proposed to favor more balanced patterns, its power could still be
affected by the presence of a highly mutated gene based on our simulations.
Thirdly, computational efficiency is a major hurdle for genome-scale screening of
mutual exclusive gene sets. Most methods (Constantinescu et al., 2016; X. Hua et al., 2016;
Y. A. Kim et al., 2017; M. D. Leiserson et al., 2016; M. D. Leiserson et al., 2015; Szczurek
& Beerenwinkel, 2014) are based on statistical tests to examine mutual exclusivity of gene
sets. However, current statistical tests have high computational burden because they
involve computationally intensive statistical modeling and/or require permutation to
calculate p-values. Furthermore, the computational burden increases dramatically as the
size of the candidate gene set increases. A few methods have been proposed to reduce this
computational burden. WExT (M. D. Leiserson et al., 2016) used a saddlepoint algorithm
to approximate the permutation test, but its computational efficiency was not sufficiently
high. WeSME (Y. A. Kim et al., 2017) proposed a weighted sampling algorithm instead of
permutation, but the algorithm was limited to examining two genes at a time. As a
compromise, most methods only focused on genes with relatively high mutation rates
and/or known to be cancer drivers. The number of genes they considered was typically less
than 1000, or even less than 100, which limited their ability to perform genome-scale
screening.
Due to these major hurdles, current mutual exclusivity analysis methods have
limited ability of analyzing the whole genome to identify novel driver genes, especially
those with low mutation frequencies. In this project, we explore methods for removing
those hurdles so as to unleash the power of mutual exclusivity analysis for genome-wide
screening of driver gene mutations. To address the challenges mentioned in the cancer
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driver mutation discovery, MEScan is developed based on a statistical test to de novo
screen mutually exclusive patterns at the genome scale. The framework has the following
key component: 1) the test statistic directly quantifies the discrepancy between the
observed level of mutual exclusivity and the expected value due to the background, where
a patient-specific and gene-specific background mutation rate is taken into account.; 2) it
incorporates a gene-specific weight to adjust for gene mutation frequencies, favoring more
balanced rather than unbalanced patterns; 3) test statistic only involves simple algebra, and
thus is very fast to calculate. Equipped with this very fast test, MEScan implement a
Markov chain Monte Carlo (MCMC) algorithm to efficiently scan for mutually exclusive
gene sets at the genomic scale, a false discovery rate (FDR) adjustment procedure to control
false positives, and a summarization procedure to select high-confidence findings. We
demonstrate our test statistics outperforms several existing methods based on simulation
studies. And our algorithm has been applied to TCGA data for genome-scale screening of
mutually exclusive gene sets.
3.2

MEScan Framework
The overview of the MEScan framework is in Figure 9. Overview of the MEScan

framework.. We propose a test statistic, TG , to examine whether a candidate gene set G
pertains to a mutually exclusive mutational pattern. The TG quantifies the difference

between the observed potential of mutual exclusivity in G with its expected value due to
background noise. A TG larger score indicates that the gene set is more likely to be mutually

exclusive. As the background mutation rate varies across patients and genes, the TG

incorporates a patient- and gene-specific background mutation rate in the calculation to
adjust for the background noise. In addition, TG includes a gene-specific weight to down47

weigh genes with very high mutation rates, which could lead to spurious unbalanced
mutually exclusive patterns. As illustrated in the figure, the candidate gene set G =
(g 2 , g 4 , g 5 ) appears to show a mutually exclusive mutational pattern. However, most of the

mutations are from gene g 2 while the other two genes, g 4 and g 5 , have very few

mutations. The apparent mutually exclusive pattern is highly unbalanced and dominated
by g 2 . To balance the impact of each individual gene on the overall pattern, our TG statistic

includes a gene-specific weight, which is inversely correlated with the gene's mutation rate,
to reduce the impact of g 2 . Furthermore, TG is very fast to calculate, which is critical for
genome-scale screening over a vast number of candidate gene sets.
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Figure 9. Overview of the MEScan framework.A key component of MEScan is a fast and
powerful statistical test, TG , for assessing mutual exclusivity of a candidate gene set. This
test accounts for a patient- and gene-specific background mutation rate (for illustration,
darker blue indicates higher and lighter blue indicates lower background mutation rate).
By using a gene-specific weight, the test also balances the impact of each gene on the
overall significance of the gene set. Based on this test, our genome-scale screening follows
a multi-step procedure. Starting from the observed mutation data matrix, an MCMC
algorithm is used to screen across candidate gene sets, where the probability of a gene set
being sampled is proportional to the TG score of that set. Next, significant gene sets are
identified with the control of the FDR. Finally, high-confidence gene sets are selected
based on the criteria that all subsets of them are also significant and they do not have
substantial overlaps.
Building upon this test, we use a multi-step procedure for genome-scale screening
of mutually exclusive gene sets. Firstly, we use an MCMC algorithm to efficiently identify
potential mutually exclusive gene sets at the genomic scale. According to the COSMIC
database (Forbes et al., 2015), somatic mutations have been identified in over 20,000 genes.
Given the vast number of candidate genes and numerous combinations of genes to form
gene sets, examining all the possible gene sets is impractical. Therefore, for each size of
candidate gene set, we construct a Markov chain such that the probability of sampling each
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gene set is proportional to the TG score of that gene set. This method allows for more

efficient screening and puts more focus on the gene sets that are more likely to be mutually
exclusive. Secondly, we identify significant mutually exclusive gene sets by implementing
an FDR control method. Finally, we select high-confidence mutually exclusive gene sets
by investigating significant gene sets across different sizes. Roughly speaking, a highconfidence mutually exclusive gene set satisfies that 1) itself and all its subsets are
significant gene sets; and 2) it does not have substantial overlap with another highconfidence mutually exclusive gene set. We expect these high-confidence mutually
exclusive gene sets, which are strongly supported by the data and distinct from each other,
are of most interest for further biological interpretation and investigation.
3.3

Testing mutual exclusivity of a single gene set
We have developed a new statistical test to examine the presence or absence of a

mutually exclusive pattern for a gene set G based on mutation data from a cohort of n
patients, while adjusting for patient- and gene-specific background mutation rate as well

as the impact of highly mutated genes. Our test statistic quantifies the observed potential
of mutual exclusivity beyond what is expected due to random background for each gene
and patient, and then takes a summation across genes and patients. To favor more balanced
patterns, each gene's contribution to the overall test is weighted by a factor inversely
correlated with its mutation rate.
Let 𝑈𝑈𝑖𝑖𝑖𝑖 take value 1 or 0 to indicate whether the ith patient satisfies the mutually

exclusive mutational pattern and the mutation occurs in a gene g ∈ G, that is,
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where Yig takes value 1 or 0 to indicate if gene g is mutated in patient i. Under the

null hypothesis of no mutually exclusive pattern, the expectation of Uig is
E�𝑈𝑈𝑖𝑖𝑖𝑖 � = P�𝑈𝑈𝑖𝑖𝑖𝑖 = 1� = η𝑖𝑖𝑖𝑖 � (1 − η𝑖𝑖𝑖𝑖 ) ≡ θ𝑖𝑖𝑖𝑖
𝑠𝑠≠𝑔𝑔,𝑠𝑠∈𝐺𝐺

where ηig is the background mutation rate for gene 𝑔𝑔 in patient 𝑖𝑖 calculated based

on the MADGiC (Korthauer & Kendziorski, 2015) method. MADGiC considers a
multiplicative model that quantifies the patient- and gene-specific background mutation
rate by a product of parameters representing a number of factors that are known to affect
the mutation rate. Those factors include patient-specific mutation rate, mutation type and

dinucleotide context (the specific nucleotide change of the mutation and whether the
mutation occurs in CpG dinucleotides), replication timing of the region and expression
level of the gene. The empirical Bayes method is used to estimate the patient-specific
mutation rate parameter, and the method of moments is used to estimate other parameters.
We quantify the contribution of gene 𝑔𝑔 in patient 𝑖𝑖 to the mutually exclusive

pattern by Zig = Uig �Uig − θig �, which calculates the difference between the observed

value of Uig and its expected value under the null hypothesis. By standardizing Zig and
taking a weighted sum across genes in G, we obtain the following statistic to quantify the
evidence of mutual exclusivity in the 𝑖𝑖th patient
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𝑇𝑇𝑖𝑖 = � 𝑤𝑤𝑔𝑔 ×
𝑔𝑔∈𝐺𝐺

3

𝑍𝑍𝑖𝑖𝑖𝑖

�𝑉𝑉𝑉𝑉𝑉𝑉�𝑍𝑍𝑖𝑖𝑖𝑖 � + 𝜆𝜆

,

(1)

where Var�Zig � = θig �1 − θig � is the variance of Zig , and λ is a small constant to

mitigate the impact of extremely small θig values. Following the suggestion of (Tusher,

Tibshirani, & Chu, 2001), we set λ to be the 5th percentile of all �θig 's, where �θig is

approximately the standard deviation of Zig because θig is usually much smaller than 1 so
3

that �θig �1 − θig � ≈ �θig .

It is important to note that in Equation (1), we include a gene-specific weight, wg ,

to adjust for the difference in mutation rate of genes in G. Specifically,
1/ ∑ni=1 Uig
wg =
.
∑s∈G[1/ ∑ni=1 Uis ]

As wg is inversely correlated with the mutation rate of gene g, it down-weighs the

impact of highly mutated genes, such as TP53, to the overall statistic, and therefore makes
the statistic favor balanced patterns. The wg removes the confounding effect of the

difference in genes’ mutation rates by standardizing the statistic to a balanced pseudo-

population, where the number of subjects having mutations in 𝑔𝑔 but not other genes in =-

G is the same for each g ∈ G. It is analogous to the inverse probability weighting in survey

sampling (Little, 1991; Pfeffermann, 1996).

Finally, we take the sum of 𝑇𝑇𝑖𝑖 over all patients and standardize it to obtain our test

statistic, 𝑇𝑇𝐺𝐺 , for mutual exclusivity of gene set 𝐺𝐺:
TG =

∑ni=1 Ti − ∑ni=1 E(Ti )
�∑ni=1 Var(Ti )
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(2)

where the expectation and variance of Ti are
E(Ti ) = �

g∈G �θ �1
ig

and

𝑉𝑉𝑉𝑉𝑉𝑉(𝑇𝑇𝑖𝑖 ) = ∑𝑔𝑔∈𝐺𝐺

wg θig �1 − θig �

2 𝜃𝜃 (1−𝜃𝜃 )3
𝑤𝑤𝑔𝑔
𝑖𝑖𝑖𝑖
𝑖𝑖𝑖𝑖

��𝜃𝜃𝑖𝑖𝑖𝑖 (1−𝜃𝜃𝑖𝑖𝑖𝑖 )3 +𝜆𝜆�

2

3

− θig � + λ
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The 𝑇𝑇𝐺𝐺 can be calculated very quickly because the formula only involves simple

algebra. This high computational efficiency is key to enable screening over a vast number
of candidate gene sets.
3.4

Genome-wide screening
The efficiency test TG makes it possible to perform genomic scale screening for

mutually exclusive gene sets from thousands of genes. However, due to the vast number
of candidate gene sets, it is still impractical to perform a mutual exclusivity test
exhaustively on each of those gene sets. Therefore, we consider an MCMC method to
screen candidate gene sets more efficiently and prioritize gene sets that are more likely to
pertain the mutually exclusive pattern. We define a probability distribution on candidate
gene sets satisfying that the probability of a candidate gene set is proportional to its TG

score. A Markov chain is then constructed to have that probability distribution as its
equilibrium distribution. Therefore, the MCMC algorithm favors sampling gene sets with
large TG scores, which are more likely to be mutually exclusive sets. A similar approach
was used in (M. D. M. Leiserson et al., 2015).
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In the implementation, we consider a separate MCMC for each size of gene sets.
For each MCMC, we use the following Metropolis-Hastings algorithm to obtain Monte
Carlo samples. For a gene set G, we define NB(G) as a collection of its neighborhood gene
sets who contain the same number of genes as 𝐺𝐺 and differ from 𝐺𝐺 by only one gene. We

require that a gene set can only transit to its neighborhood gene sets. Specifically, at each
MCMC iteration, the proposed state 𝐺𝐺' given the current state 𝐺𝐺 is a random sample from
𝑁𝑁𝑁𝑁(𝐺𝐺). The Metropolis acceptance probability for 𝐺𝐺' is

TG′ τ
r(G, G = min �1, � � �,
TG
′)

3.5

where τ is a tuning parameter to control the acceptance rate to be around 30%.

Determining a cutoff value to control the FDR

We identify significantly mutually exclusive gene sets by controlling the FDR<0.05
based on the local fdr method from a previous publication (Efron, 2004b). The local fdr
method considers the observed distribution of 𝑇𝑇𝐺𝐺 as a mixture of null and non-null
distributions. It empirically estimates the null and non-null distributions for possibly non-

independent test statistics of large-scale simultaneous hypothesis testing. The FDR is then
calculated based on the empirical null and non-null distributions. A cutoff value of 𝑇𝑇𝐺𝐺

corresponding to FDR < 0.05 is determined so that gene sets with 𝑇𝑇𝐺𝐺 scores larger than
the cutoff value are considered as significantly mutually exclusive. The cutoff value is
determined for each size of gene sets separately. Note that the original method in (Efron,
2004b) requires using the 𝑇𝑇𝐺𝐺 's of all candidate gene sets to estimate the empirical null and

non-null distributions and determine the 𝑇𝑇𝐺𝐺 cutoff value, which is computationally

intractable for our situation. As those gene sets are randomly selected, they are likely to
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represent the distribution of TG in all candidate gene sets. Therefore, instead of using all

candidate gene sets, we randomly sample 107 gene sets to estimate the empirical null
distribution and determine the TG cutoff value for each size of gene sets. Based on real data
analysis, as shown in Figure 14. TG cutoff value estimation. For each size of candidate gene

sets, the cutoff value of TG for controling FDR < 0.05 was estimated by sampling 107 (red
square) or 108 (blue diamond) candidate gene sets., sampling 107 gene sets are sufficient
to obtain stable cutoff values.
3.6

Identifying high-confidence mutually exclusive gene sets
By applying the TG cutoff value as described in the last subsection, we can identify

a number of significant mutually exclusive gene sets with FDR < 0.05 for each size of gene
sets. Let ℳ be a collection of the significant gene sets across all sizes.

Based on our experience, there can be a large number of gene sets in ℳ and many

of those gene sets overlap with each other. To promote more robust and focused inferences,
we further define high-confidence mutually exclusive gene sets, satisfying that 1) all
subsets are also significantly mutually exclusive; and 2) different gene sets do not have
substantial overlaps. A two-step procedure is used to select high-confidence mutually

exclusive gene sets. The first step identifies all maximal cliques in ℳ. A clique is defined
as a gene set (size ≥ 3) such that itself and all of its subsets (size ≥ 2) are all in ℳ. A

maximal clique is a clique that cannot be expanded by including any additional gene. These
maximal cliques are likely to be real mutually exclusive sets because they are validated by
all their subsets. Note that we do not consider gene sets of size 2 as cliques because they
do not have subsets to validate. The second step removes largely overlapped maximal
cliques of the same size. For maximal cliques of size > 3, if the number of overlapped genes
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between two maximal cliques of the same size is > 50% of the size, we remove one of them
with a lower TG score. For maximal cliques of size = 3, because the size is too small to

define meaningful overlaps, we simply select the top 100 maximal cliques with the largest TG scores. After the two-step procedure, the remaining maximal cliques are considered as
high-confidence mutually exclusive gene sets.
3.7
3.7.1

Results
Simulation studies
We performed simulation studies to evaluate the performance of MEScan and

compared to the following five existing methods: MEGSA, Dendrix (version 0.3), TiMEx
(version 0.99.0), WExT (weighted-row exclusivity test, version 1.3.0) and CoMEt. For
CoMEt, we used the WExT row-exclusivity test implementation as suggested by the paper
(M. D. Leiserson et al., 2016). To mimic a real-world situation, the simulated datasets were
generated based on the TCGA ovarian cancer dataset described in the Real data analysis
subsection.
3.7.1.1 Simulation studies to evaluate methods' performance in identifying subsets of a
true mutually exclusive gene set without the presence of highly mutated genes
As the goal of the analysis is to identify truly mutually exclusive mutation patterns
while avoiding spurious patterns, the following simulation studies were conducted to
evaluate and compare each method's performance in ranking candidate gene sets. We
randomly selected 200 patients and 3 genes from TCGA ovarian cancer dataset and
artificially added a mutually exclusive mutational pattern on 10%, 20%, 30%, or 40% of
patients, which was referred to as the coverage. We considered two different mutually
exclusive mutational patterns, one with a 1:1:1 ratio of mutation frequencies for the three
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genes (equal number of mutations in each gene) and the other with a 3:2:1 ratio of mutation
frequencies. We additionally included 17 other genes, each has at least 5 mutations in the
TCGA ovarian cancer dataset, as “noisy” genes without any mutually exclusive pattern.
We considered two different approaches to select those genes. One approach was to
randomly select 17 genes from the real data. The other was to intentionally include TP53,
which had a high mutation frequency of 94.6%, and randomly select the other 16 genes.
This second approach aimed to assess each method's performance in the presence of a
highly mutated driver gene but not part of the mutually exclusive pattern, where such a
gene could yield spurious unbalanced mutually exclusive patterns by random chance.
We first evaluated methods' performance in identifying the true 3-gene mutually
exclusive gene set. Under each scenario, we applied each method (except for TiMEx) to
all candidate gene sets of size 3 and identified the top-ranked gene set. Here, the candidate
gene sets were ranked based on the TG score for MEScan, the weight W for Dendrix, the

p-value for CoMEt, WExT and TiMEx, and the likelihood for MEGSA. Note that because

TiMEx is computationally intensive, we only applied it to a smaller subset of candidate
gene sets, i.e., the union of top 10 gene sets ranked by each of the other methods and the
gene set with the true mutual exclusive pattern, which may bias the result in favor of this
method. Our simulations were replicated 100 times and the frequency that the top-ranked
gene set was the gene set containing the true mutually exclusive mutation pattern we
generated was calculated, which was referred to as the power.
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Figure 10. Comparison of power for identifying a true mutually exclusive gene set based
on simulations. Each simulated dataset contained 20 genes, including 3 genes with a true
mutually exclusive mutational pattern and the other 17 genes without any pattern.
Simulations were replicated 100 times and the power was calculated as the frequency that
the top-ranked gene set was the 3-gene set with the true mutually exclusive mutational
pattern. Four scenarios were considered. A) The ratio of mutation frequencies was 1:1:1
for the 3 genes and the other 17 genes did not include a highly mutated gene; B) the ratio
of mutation frequencies was 3:2:1 for the 3 genes and the other 17 genes did not include a
highly mutated gene; C) the ratio of mutation frequencies was 1:1:1 for the 3 genes and the
other 17 genes included a highly mutated gene; and D) the ratio of mutation frequencies
was 3:2:1 for the 3 genes and the other 17 genes included a highly mutated gene.
Figure 10 shows the simulation results. In all scenarios, MEScan had the highest
power compared to other methods, especially when the coverage was low. For example,
when a true mutually exclusive pattern with equal number of mutations in each of the three
genes was presented in 10% of patients, MEScan was able to achieve 80% power (Figure
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10A). In contrast, all other methods had power less than 25%. This is likely due to the
adjustment of the background mutation rate by MEScan, which provides a better detection
of true patterns against spurious patterns coming from random noise.
3.7.1.2 Simulation studies to evaluate methods' performance in identifying subsets of a
true mutually exclusive gene set with the presence of highly mutated genes
We next assessed the impact of a highly mutated noisy gene (TP53) that was not
part of the true mutually exclusive pattern. Figure 11. Comparison of power for identifying
subsets of a true mutually exclusive gene set based on simulations. Each simulated dataset
contained 20 genes, including 3 genes with a true mutually exclusive mutational pattern
and the other 17 genes without any pattern. Simulations were replicated 100 times and the
power was calculated as the frequency that the top-ranked 2-gene set was a subset of the
true 3-gene mutually exclusive mutational pattern. Four scenarios were considered. A) The
ratio of mutation frequencies was 1:1:1 for the 3 genes and the other 17 genes did not
include a highly mutated gene; B) the ratio of mutation frequencies was 3:2:1 for the 3
genes and the other 17 genes did not include a highly mutated gene; C) the ratio of mutation
frequencies was 1:1:1 for the 3 genes and the other 17 genes included a highly mutated
gene; and D) the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17
genes included a highly mutated gene. compares the power of each method in the absence
(top panels) vs. presence (bottom panels) of TP53. MEScan was able to maintain the power
after the addition of the highly mutated gene, indicating that it was robust to such a gene
that could cause spurious unbalanced patterns by random chance. In contrast, the power of
all other methods decreased. Dendrix did not have any power even when the coverage
increased, which is as expected, because it was sensitive to unbalanced spurious patterns.
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In fact, the top-ranked gene set from Dendrix was always a set containing TP53. CoMEt,
which used a conditional method to reduce the bias towards unbalanced patterns, also had
substantial decrease in power. Therefore, the conditional method appeared not adequately
address the issue of unbalanced spurious patterns.
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Figure 11. Comparison of power for identifying subsets of a true mutually exclusive gene
set based on simulations. Each simulated dataset contained 20 genes, including 3 genes
with a true mutually exclusive mutational pattern and the other 17 genes without any
pattern. Simulations were replicated 100 times and the power was calculated as the
frequency that the top-ranked 2-gene set was a subset of the true 3-gene mutually exclusive
mutational pattern. Four scenarios were considered. A) The ratio of mutation frequencies
was 1:1:1 for the 3 genes and the other 17 genes did not include a highly mutated gene; B)
the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17 genes did not
include a highly mutated gene; C) the ratio of mutation frequencies was 1:1:1 for the 3
genes and the other 17 genes included a highly mutated gene; and D) the ratio of mutation
frequencies was 3:2:1 for the 3 genes and the other 17 genes included a highly mutated
gene.
3.7.1.3 Simulation studies to evaluate methods' performance in identifying the true
mutually exclusive gene set across candidate gene sets of different sizes
We adapted the same simulation scenarios and applied each methods to all
candidate gene sets of sizes from 2 to 6. We calculated the fraction of simulations that the
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top-ranked gene set was exactly the true 3-gene mutually exclusive set, is a subset of the
true set, contains the true set, or otherwise. Compared to other methods, MEScan yielded
the highest fraction of simulations with the top-ranked gene set being the true mutually
exclusive set when the coverage was low. It was also robust to the presence of a highly
mutated noisy gene. Figure 12 Simulation results for applying MEScan, MEGSA, Dendrix,
WExT and CoMEt across different sizes (2 to 6) of candidate gene sets. Bar graphs show
the fractions of simulations that the top-ranked gene set is exactly the true 3-gene mutually
exclusive set (green), is a subset of the true set (blue), contains the true set (yellow), or
otherwise (red). Each simulated dataset contained 20 genes, including 3 genes with a true
mutually exclusive mutational pattern and the other 17 genes without any pattern.
Simulations were replicated 100 times. Four scenarios were considered. A) The ratio of
mutation frequencies was 1:1:1 for the 3 genes and the other 17 genes did not include a
highly mutated gene; B) the ratio of mutation frequencies was 3:2:1 for the 3 genes and
the other 17 genes did not include a highly mutated gene; C) the ratio of mutation
frequencies was 1:1:1 for the 3 genes and the other 17 genes included a highly mutated
gene; and D) the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17
genes included a highly mutated gene.shows the results for all the methods. For the
scenarios that the ratio of mutation frequencies of the three genes in the true set was 1:1:1,
MEScan had the largest fraction of simulations that ranked the true 3-gene set to the top
among all methods when the coverage was 0.1 to 0.3, while CoMEt had the largest fraction
when the coverage was 0.4. For the scenarios that the ratio of mutation frequencies of the
three genes in the true set was 3:2:1, MEScan more frequently ranked a 2-gene subset of
the true set to the top. This is as expected because one of the three genes had a low mutation
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frequency, making it more dicult to be identied. For the purpose of identifying driver genes,
MEScan was conservative since all genes in the top-ranked set were part of the true signal.
In contrast, other methods tended to more frequently rank larger gene sets, containing some
noisy genes in addition to genes in the true set, to the top, which was anti-conservative. In
addition, MEScan was still able to identify the true 3-gene set in a fraction of simulations
under low coverage situation (coverage = 0.1 or 0.2), where other methods were unable to
identify the true set. Furthermore, MEScan's performance remained the same in the absence
or presence of a highly mutated noisy gene, suggesting that MEScan was robust to the
presence of such a gene. In contrast, the top-ranked gene sets based on Dendrix, WExT
and CoMEt were almost always neither the true set nor a superset of the true set in the
presence of a highly mutated noisy gene.

63

64

Figure 12 Simulation results for applying MEScan, MEGSA, Dendrix, WExT and CoMEt
across different sizes (2 to 6) of candidate gene sets. Bar graphs show the fractions of
simulations that the top-ranked gene set is exactly the true 3-gene mutually exclusive set
(green), is a subset of the true set (blue), contains the true set (yellow), or otherwise (red).
Each simulated dataset contained 20 genes, including 3 genes with a true mutually
exclusive mutational pattern and the other 17 genes without any pattern. Simulations were
replicated 100 times. Four scenarios were considered. A) The ratio of mutation frequencies
was 1:1:1 for the 3 genes and the other 17 genes did not include a highly mutated gene; B)
the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17 genes did not
include a highly mutated gene; C) the ratio of mutation frequencies was 1:1:1 for the 3
genes and the other 17 genes included a highly mutated gene; and D) the ratio of mutation
frequencies was 3:2:1 for the 3 genes and the other 17 genes included a highly mutated
gene.
3.7.1.4 Simulation studies to evaluate methods' performance in controlling the false
discovery rate (FDR)
We further evaluated the FDR control of our method. In the absence of a highly
mutated noisy gene, the observed FDR was around the nominal FDR. In the presence of a
highly mutated noisy gene, the observed FDR was smaller than thee nominal FDR. These
results suggests that our method was able to control the FDR. We considered the same four
simulation scenarios as described in the main text. We investigated all candidate gene sets
of size 3, and calculated the observed FDR corresponding to the nominal FDR of 0.01,
0.05, 0.1, and 0.2. Note that the null hypothesis for a mutual exclusivity test is that the three
genes do not have any mutually exclusive pattern. The alternative hypothesis is that there
is a mutually exclusive pattern, which includes both the case of a full mutually exclusive
pattern among all the three genes and the case of a partial mutually exclusive pattern in two
of the three genes. Both cases are considered as true positives in our calculation. In our
simulations, the full and partial patterns are overlapping, and thus correlated with each
other. Figure 12 Simulation results for applying MEScan, MEGSA, Dendrix, WExT and
CoMEt across different sizes (2 to 6) of candidate gene sets. compares the nominal FDR
versus the observed FDR. In the absence of a highly mutated noisy gene, the observed FDR
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was around the nominal FDR. In the presence of a highly mutated noisy gene, the observed
FDR was smaller than thee nominal FDR. These results suggests that our method was able
to control the FDR.

Figure 13 Evaluation of the FDR control based on simulations. Each simulated dataset
contained 20 genes, including 3 genes with a true mutually exclusive mutational pattern
having a coverage of 0.2 and the other 17 genes without any pattern. Simulations were
replicated 100 times. Four scenarios were considered. A) The ratio of mutation frequencies
was 1:1:1 for the 3 genes and the other 17 genes did not include a highly mutated gene; B)
the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17 genes did not
include a highly mutated gene; C) the ratio of mutation frequencies was 1:1:1 for the 3
genes and the other 17 genes included a highly mutated gene; and D) the ratio of mutation
frequencies was 3:2:1 for the 3 genes and the other 17 genes included a highly mutated
gene.
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Our proposed identification of high-confidence mutually exclusive gene sets
provides a way to further select full patterns out of partial patterns. This is because a highconfidence mutually exclusive gene set requires that all its subsets are also significantly
mutually exclusive. For a gene set containing a partial pattern, some of its subsets may not
contain >1 genes from the mutually exclusive pattern, and thus are likely to be nonsignificant. Therefore, the identification of high-confidence mutually exclusive gene sets
can potentially filter out those gene sets with partial patterns. To demonstrate this, we
performed high-confidence mutually exclusive gene sets identification based on the
simulated datasets. In all simulations, the true 3-gene set always remained in the highconfidence sets as long as the high-confidence sets was non-empty. For balanced pattern
situations (scenarios A and C), in 44% to 50% of simulations, the high-confidence sets
only contains a single gene set, which is the true set, suggesting that our method was able
to filter out gene sets with partial pattern. For less balanced pattern situations (scenarios B
and D), our method was able to identify the single true gene set in 23% to 24% of
simulations. The reduced percentage compared to balanced pattern situations was due to
the fact that there was a gene with low coverage in the true set under less balanced
situations, which was harder to detect. It should also be pointed out that in 20% to 50% of
simulations, the resulting high-confidence set was empty, suggesting that the selection of
high-confidence set was very stringent so that the true set could sometimes be filtered out.
To sum up, the identification of high-confidence mutually exclusive gene sets appears to
be a conservative approach to filtering out gene sets with partial patterns.
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3.7.2

Time cost comparison
Computational time is very critical for a mutual exclusivity test due to the vast

number of candidate gene sets needing to be examined. We compared the computational
time of MEScan, MEGSA, Dendrix, WExT and CoMEt for assessing 1000 candidate gene
sets for each of the size 3 to 7 based on 200 patients randomly selected from the TCGA
ovarian cancer dataset. Note that TiMEx was not included in the comparison, because it
was substantially slower than other methods. Table 4 presents the running time of each
method. MEScan was the fastest method. The only other method that was on the same scale
as MEScan is Dendrix. However, as pointed out by Leiserson et al. (2015) (M. D.
Leiserson et al., 2015) and also observed in our simulations, Dendrix did not adjust for the
impact of highly mutated genes, and therefore could lead to spurious results. Apart from
Dendrix, MEScan was at least two orders of magnitude faster than the rest three methods.
For example, it took MEScan only 0.017 seconds to analyze 1000 gene sets of size 3, while
the other three methods took more than 8 seconds. In addition, MEScan only had a less
than 2-fold increase in computational time as the size of gene set increased from 3 to 7. In
contrast, CoMEt and WExT had a 10-fold increase in computational time. Therefore,
MEScan provides a very fast and robust test that is instrumental for genome-scale screening
of mutually exclusive gene sets.
Table 4. Comparison of computational time. The reported computational time (in seconds)
was for analyzing 1000 gene sets of a given size.
Size of gene
set

3
4
5
6
7

MEScan

MEGSA

Dendrix

WExT

CoMEt

0.017
0.021
0.022
0.023
0.023

14.604
18.166
26.26
37.285
54.675

0.052
0.056
0.06
0.061
0.076

8.807
12.791
31.575
50.402
96.574

8.488
12.701
23.611
46.922
85.256
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3.7.3

Choosing cutoff values of 𝑇𝑇𝐺𝐺 to control FDR

In genome-scale screening, a cutoff value of TG is determined based on the

empirical distribution of TG (Efron, 2004a) to control for the FDR for each size of gene

sets. As it is impractical to obtain TG for all candidate gene sets, we randomly selected a

fraction of gene sets to estimate the empirical distribution of TG for each gene set size and

then determine the cutoff value. To determine how large the fraction is needed to obtain
stable cutoff values, Figure 14 compared the cutoff value calculated from 107 or 108

randomly selected candidate gene sets for gene set sizes 3 to 7 based on the TCGA ovarian
cancer dataset. The cutoff value determined using 107 gene sets was stable. Increasing the

number to 108 did not lead to any notable change. As the computational time of calculating
TG 's for 107 gene sets is acceptable in practice, we used this number in our real data

analysis.
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Figure 14. TG cutoff value estimation. For each size of candidate gene sets, the cutoff value
of TG for controling FDR < 0.05 was estimated by sampling 107 (red square) or 108 (blue
diamond) candidate gene sets.
3.7.4

Whole genome data analysis
We applied our method to TCGA glioblastoma (Brennan et al., 2013), squamous

cell lung cancer (Cancer Genome Atlas Research, 2012), ovarian cancer (Cancer Genome
Atlas Research, 2011), pan-cancer (Cancer Genome Atlas Research et al., 2013; Kandoth
et al., 2013), and breast cancer (Cancer Genome Atlas, 2012) studies. All the data were
downloaded from Synapse (syn1729383) (Kandoth et al., 2013). For each dataset, we
limited our analysis to non-synonymous mutations and focused on non-synonymous
mutations and filtered out genes with no more than one mutation. The filtered datasets
contain 3193 to 16984 genes. We applied MEScan and searched for mutual exclusive gene
sets of size between 2 and 7. For each gene set size, 4 independent MCMC chains, each
having 108 iterations with 5 × 105 burn-in iterations, were generated using 4 different
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random seeds and the results were pooled together. To control for FDR, we randomly
selected 107 gene sets of a given size to estimate the empirical null distribution of TG and
FDR. We chose the cutoff value of TG score such that FDR < 0.05 and called gene sets

with TG scores higher than the cutoff value as significant mutually exclusive gene sets.

Finally, high-confidence mutually exclusive sets were determined by investigating the
consensus of mutually exclusive gene sets across different sizes. Below, we focused on
some of these high-confidence mutually exclusive sets and explored their biological
interpretations. The selection of these interesting cases was based on the biological
importance and relevance of these gene mutations as well as the clinically actionable
mutations of interest.
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Figure 15. High-confidence mutually exclusive gene sets identified from real data analysis.
MEScan was applied to identify high-confidence mutually exclusive gene sets based on A)
TCGA glioblastoma (n=290); B) TCGA lung squamous cell carcinoma (n=174); C) TCGA
ovarian cancer (n=314); and D) TCGA pan-cancer datasets (n=3205). One selected highconfidence mutually exclusive gene set from each dataset was presented in this figure.
3.7.4.1 Glioblastoma
We identified a high-confidence mutually exclusive set with IDH1, EGFR, PTEN
and PIK3CA (Figure 15A). Aberrant PI3K/Akt signaling is frequently observed in cancers
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including glioma, which often is achieved by loss of the PI3K inhibitor PTEN (phosphatase
and tensin homolog) or gain-of-function mutations of EGFR (X. Li et al., 2016; H. Xu et
al., 2017) or PI3KCA (Carracedo & Pandolfi, 2008). IDH1 is a NADP-dependent enzyme
that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) in the

TCA cycle. IDH mutations are frequently present in gliomas and result in a gain of enzyme
function of NADPH-dependent reduction of α-ketoglutarate to 2-hydroxyglutarate that
promotes tumorigenesis (Philip et al., 2018). Mutant IDH1 activates mTOR signaling
downstream of the PI3K/AKT/TSC1/2 pathway by inhibiting KDM4A, an α -KG-

dependent histone demethylase (Carbonneau et al., 2016). Thus, in glioblastoma, we have
identified three regulators of PI3K/AKT/mTOR signaling.
3.7.4.2 Squamous cell lung cancer
A high-confidence mutually exclusive set we identified consists of three genes,
kelch-like ECH-associated protein 1 (KEAP1), phosphatase and tensin homolog (PTEN)
and nuclear factor erythroid-2-related factor 2 (NFE2L2/NRF2), see Figure 15B. NRF2 is
a transcription factor and critical regulator of response to oxidative stress. KEAP1 is a
negative regulator of NRF2, and in response to oxidative stress, NRF2 is released from
KEAP1 where it travels to the nucleus and activates transcription of target genes, that are
generally anti-oxidants. When KEAP1 is mutated, NRF2 accumulates (X. Chen, Zhang,
Zhang, & Gao, 2019). Constitutive activation of NRF2, either through mutations in NRF2
itself or the regulatory partner KEAP1, is recognized to increase tumorigenesis as well as
drive resistance to chemotherapies. In addition, many lung cancers have constitutive NRF2
activation in the absence of NRF2 and KEAP1 mutations (Kerins & Ooi, 2018). PTEN has
recently emerged as a negative regulator of NRF2, and loss of PTEN is associated with
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constitutive activation of NRF2 (Best et al., 2018). Therefore, our analysis has identified
two regulators of a final common transcription factor, strongly implicated in tumorigenesis
and resistance to chemotherapy.
3.7.4.3 Ovarian cancer
Breast cancer gene 1 (BRCA1), neurofibromatosis type (NF1) and cyclindependent kinase (CDK) 12 was identified as a high probability mutually exclusive gene
set in ovarian cancer (Figure 15C). CDK12 is transcriptional regulator of DNA damage
response (DDR) genes including those involved in the homologous recombination (HR)
like BRCA1 (Joshi, Sutor, Huntoon, & Karnitz, 2014; Paculov\'a & Kohoutek, 2017), via
phosphorylation of the RNA polymerase II C-terminal domain. Loss of function mutations
of CDK12 result in compromised DDR and homologous recombination, which is observed
in ovarian cancers(Joshi et al., 2014). Neurofibromatosis is a hereditary syndrome in which
individuals typically develop benign neurofibromas because of neurofibromin 1 (NF1)
mutations, but are also at increased risk of breast cancer(Jeon, Kim, Lim, Choi, & Suh,
2015). Recent work demonstrated an association between NF1 deletions and ESR1, the
gene for the estrogen receptor (ER) expression and ER positivity (Dischinger et al., 2018).
In breast cancer, NF1 binds to and represses ER and loss of function mutations of NF1
activate ER transcriptional pathways (Chang et al., 2018). Like breast cancer, ovarian
cancer is a hormone-responsive cancer with ER present in about 60–100% of ovarian
cancers (Modugno et al., 2012). It’s likely that for ovarian cancers, there are two subtypes.
One is driven by mutations in CDK12/BRCA signaling while the other is driven by
mutations in NF1/ER signaling. Our gene set analysis has thus identified mechanisms of
tumorigenesis of ovarian cancer.
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3.7.4.4 Pan-cancer
CDKN2A, NPM1, RPL22, SMC1A was identified as a high-confidence mutually
exclusive gene set from TCGA pan-cancer data (Figure 15D). P53 is a well-established
tumor suppressor in human cancer. CDKN2A encodes p14ARF, which inhibits MDM2
and promotes p53 function such as cell cycle control, apoptosis and tumor suppression
(Sherr, 2006). NPM1 (nucleophosmin) complexes with and stabilizes p14ARF (Sherr,
2006). Mutated NPM1 fails to protect p14ARF from degradation and attenuates the ability
of p14ARF to promote p53 function (Colombo et al., 2006) NPM1 also directly interacts
with p53 and positively regulates the stability and transcriptional activity of p53 (Colombo,
Marine, Danovi, Falini, & Pelicci, 2002). RPL22 (Ribosomal protein L22) is highly
mutated in various human cancers. Studies have shown that RPL22 binds with and inhibits
MDM2 E3 ligase and thus functions as a p53 positive regulator (Cao et al., 2017). Finally,
SMC1A is a component of the cohesin complex that plays a crucial role during mitosis in
holding sister chromatids together from DNA replication in S phase to anaphase to ensure
proper chromosome separation. SMC1A mutations would impact cohesin functions
(Hirano, 2006) and would theoretically result in error-prone chromosome replication and
segregation, which may induce p53-mediated cell cycle control, although it has not been
experimentally confirmed. The cohesin complex has been shown to bind to the
transcription start sites of p53 and mdm2, and the knockdown of Rad21 (a cohesin
component) increased their transcription (Rhodes et al., 2010). It is possible that SMC1A
mutations would enhance p53 and mdm2 transcription. Thus pan-cancer mutations in
CDKN2A, NPM1, RPL22, and SMC1A can be functionally connected through the
p14ARF-MDM2-p53 tumor suppressor pathway.
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3.7.5

Real world validation and comparison
We used four real data sets to validate our method from different aspects. We also

tried to compare our method to existing ones when possible. Note that we attempted to try
existing methods on the whole-genome real data examples presented in the last subsection.
However, all attempts with those methods failed to finish. Dendrix ran out of computer
memory (i.e > 64 GB of RAM). MEGSA, CoMEt and WEXT did not finish after using
over 6 days of CPU time. Therefore, we compared our methods to others using a smaller
scale real data example presented in the first validation study of this subsection, where
some of the existing methods were able to generate results.
Our first validation study considered the pan-cancer data on 299 driver genes from
TCGA MC3 (Li Ding et al., 2018) to assess whether MEScan as well as other methods can
identify the mutually exclusive patterns reported in the paper. Two sets of analyses were
performed. The first set of analyses focused on examining all candidate gene sets of size 2.
Ding et.al (Li Ding et al., 2018) reported 8 mutually exclusive gene sets based on the exact
Mantel-Haenszel test. MEScan was able to identify all those 8 gene sets as significantly
mutually exclusive. In contrast, WExT was able to identify 7, CoMEt was able to identify
1, Dendrix was unable to identify any of those gene sets, and MEGSA was unable to
complete the analysis with 6 days of CPU time. The second set of analyses focused on
examining candidate gene sets of size >2. Ding et.al (Li Ding et al., 2018) reported 4 such
gene sets. MEScan was able to identify all of them as significantly mutually exclusive. In
contrast, Dendrix was unable to identify any of those gene sets, and other methods were
unable to complete the analysis with 6 days of CPU time. Our second validation study
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considered the set of BRAF and NRAS, whose mutations are known to be mutually
exclusive in melanoma (Akbani et al., 2015). We applied each method to TCGA melanoma
data (Akbani et al., 2015) (n=253). We focused on all gene sets of size 2 and investigated
whether a method was able to identify the gene set of BRAF and NRAS. MEScan gave a
𝑇𝑇𝐺𝐺 score of 125.6 for the set of BRAF and NRAS, which is highly significant. In contrast,

other methods were unable to finish after using over 6 days of CPU time. Our third
validation study used an independent large-scale cohort, PCAWG (Consortium, 2020), to

validate the our findings from TCGA pan-cancer analysis. The PCAWG cohort contains
1810 cancer patients after excluding overlapped patients between PCAWG and TCGA.
After filtering out a few genes with no observed mutations in the PCAWG cohort, we
examined a total of 149 high-confident mutually exclusive gene sets we identified from the
TCGA pan-cancer cohort. 95% of those gene set were also significantly mutually exclusive
in the PCAWG cohort. Our fourth validation study used an independent cohort of 2,433
primary breast tumors (Pereira et al., 2016) to validate our findings from TCGA breast
cancer analysis. Because the validation cohort sequenced a panel of 173 genes, we focused
our analysis on high-confidence gene sets consisting of those genes. 84% of those gene
sets remained significant in the validation cohort. These four validation studies suggested
that MEScan was able to identify known mutually exclusive patterns and provide
reproducible results.
3.8

Discussion
We have introduced a statistical framework, MEScan, for accurate and efficient

genome-wide de novo discovery of mutually exclusive gene sets. Our framework uses a
simple yet powerful statistical test for identifying mutually exclusive gene sets. The test

77

allows adjustment of background mutation rate, mitigates the impact of highly mutated
genes, and is very fast to calculate. Coupled with this test is an MCMC algorithm to
efficiently screen candidate gene sets at the genomic scale. MEScan is able to search
through thousands of candidate genes without restricting to known cancer drivers or genes
with high mutation rates. To reduce false positives, we use an FDR control procedure to
identify significant gene sets and a summarization method to further select high-confidence
mutually exclusive gene sets. Although our method focuses on detecting mutual exclusive
patterns, it could potentially be extended to detect other important mutational patterns, such
as co-occurrence patterns (Avivar-Valderas et al., 2018; Li Ding et al., 2018; Thomas et
al., 2007), but the formula needs to be tweaked towards quantifying those specific patterns.
Another important extension of our method is to include somatic copy number variations
in the analysis.
We noticed that mutual exclusivity could originate from different mechanisms. The
focus of most current research is on mutations of genes from the same biological pathway.
However, gene mutations specific to different cancer subtypes could also form a mutually
exclusive pattern. For example, from TCGA ovarian cancer data, we identified a highconfidence mutually exclusive gene set of BRCA1, NF1 and CDK12, which is likely to
contain two different subtypes of ovarian cancer driven by CDK12/BRCA1 signaling and
NF1/ER signaling, respectively. Therefore, a potential new use of mutual exclusivity
analysis might be to identify cancer subtypes and subtype-specific gene mutations. Further
research in this area will be of great interest. Furthermore, mutually incompatible mutations
(e.g. synthetically lethal mutations) would also produce mutual exclusivity in mutation as
possible.
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One limitation of MEScan is that it does not account for intratumoral heterogeneity.
Mutations identified using whole-exome bulk sequencing usually come from a mixture of
multiple subclones within a tumor(McGranahan & Swanton, 2017). Delineating the
intratumor heterogeneity (Schwartz & Sch\"a, 2017) could provide a cleaner signal to
improve mutual exclusivity analysis. Furthermore, recent advances in single-cell
sequencing technologies (Zhang et al., 2019) hold the promise of revealing intratumor
heterogeneity at a much higher resolution. With the accumulation of such data, performing
mutual exclusivity analysis at the single cell level will be an interesting topic for future
research.
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CHAPTER 4. FastCount: A Fast Gene Count Software for Single Cell and Bulk RNAseq Data
4.1
4.1.1

Introduction
Bulk RNA-seq gene quantification
RNA sequencing (RNA-seq) has become one of the most commonly used

techniques for transcriptome profiling in a wide spectrum of biomedical and biological
research. Analyzing RNA-seq reads to quantify expression at each gene locus is the first
step towards any downstream biological interpretation.
There are two popular gene expression estimation methods: gene count and
transcript abundance. Gene count is essentially the total number of reads sequenced within
a gene. Many popular statistical differential expression methods such as DESeq2 (Love et
al., 2014) and edgeR (Robinson et al., 2010) take gene count as input. They model it as
negative binomial distribution to deal with biological variability and overdispersion and
determines differential expression using exact tests (Seyednasrollah et al., 2015). Several
tools such as featureCounts (Liao et al., 2014) and HTSeq (Anders et al., 2015) are used to
obtain the gene counts. These softwares require several preprocessing steps on the raw
RNA-seq reads before performing read counts: 1) generally, a read trimming step is
necessary to remove adapter sequences and low-quality bases from the FASTQ files
(Bolger et al., 2014; Martin, 2011a). This improves the mappability of the reads during the
downstream alignment step. The quality trimming criteria, such as minimum base quality
score or a number of bases to be trimmed on start or end of each read, are selected
empirically by the users. The processing time ranges from 10 ~ 60 minutes depending on
the different algorithms. 2) next, trimmed reads are aligned to either the reference genome
or the reference transcriptome using RNA-seq mappers, such as Bowtie2 (Langdon) and
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STAR (Bohnert, Vivas, & Jansen), to generate BAM files. 3) Aligned reads in the BAM
files are assigned to genes based on the genomic locations provided in the Gene Annotation
File (GTF) for gene-level read counts. Although there are some efficient algorithms
available, such as featureCounts to summarize read counts from the BAM file, read
alignment is computationally intensive, requiring large memory and CPU time.
Alternatively, read counts can be derived from transcript abundance using tools specially
designed for transcript-level abundance estimation. Transcript expression is first quantified
using tools like RSEM (B. Li & Dewey, 2011), Kallisto (Bray, Pimentel, Melsted, &
Pachter, 2016) and Salmon (Patro, Duggal, Love, Irizarry, & Kingsford, 2017), followed
by additional gene-level expression estimation. RSEM, first performs read mapping using
the read aligner mentioned above and uses the Expectation Maximization (EM) algorithm
to estimate abundances at the isoform and gene levels. However, RSEM does not scale
well due to the high computational requirements. Kallisto and Salmon on the other hand,
are alignment-free algorithms where reads are not directly aligned but rather assigned to
the most likely transcript that generated them using 𝑘𝑘-mers. Those methods avoid the time-

consuming read alignment steps and report expression abundance (Teng et al., 2016) on
transcript levels. Gene-level read counts are estimated using the transcript-level expression
by customized scripts or third-party tools to correct gene length changes from differential
isoform usage {Soneson, 2015 #162}. Therefore, current methods suffer from the
following problems: the accuracy of alignment-based methods depends heavily on the
performance of the aligners (Baruzzo et al., 2017) and the scalability is poor in large scale
study; assigning reads to transcripts is more challenging than to gene due to the repetitive
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sequences among the transcripts (Teng et al., 2016); and no efficient tools that are specially
designed to correctly derive gene-level abundance (Soneson et al., 2015).
4.1.2

Single-cell RNA-seq gene quantification
Bulk RNA-seq quantifies the overall transcriptome changes in a collection of cells

with the assumption that cells are homogenous within the sample. However, more
evidences have shown that (Michael S. Lawrence et al., 2013) (Burrell et al., 2013) tumor
cells have highly distinct cell types with each types of cells at different cell states. Bulk
RNA-seq averages out the gene expression profile leading to the cell-to-cell variability
information unusable (Suva & Tirosh, 2019). The advent of single cell RNA-seq (Klein et
al., 2015; Macosko et al., 2015; Zheng et al., 2017) enables scientists to characterize the
transcriptomic response of cancer cells under different treatment, understand intratumor
expression heterogeneity and infer pseudo-time ordering in cancer development. The
increasingly usage of scRNA-seq in the cancer research community necessitates the
development of efficient and accurate algorithm to handle the large amount of scRNA-seq
data.
The goal of scRNA-seq is to generate abundance × cell expression matrix that can

be used for the downstream analyses. Similar to the bulk RNA-seq, the first step in
analyzing scRNA-seq data is to assign reads to the reference transcriptome for quantifying
gene expression level in each cell. In scRNA-seq , gene counts-based quantification which

is the popular approach in bulk RNA-seq analysis (Conesa et al., 2016; Soneson et al.,
2015), is largely biased due to cDNA amplification step in the library preparation (Wang
& Navin, 2015) leading to distorted estimation of single cells expression level. Recent
scRNA-seq protocols (Klein et al., 2015; Macosko et al., 2015; Zheng et al., 2017) have
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employed the unique molecular identifiers (UMIs) technique to label the original RNAs
before the amplification step to mitigate the bias (W. Chen et al., 2018). Instead of using
gene counts, many published statistical methods are focusing on UMI-based count matrix,
which is the total number of UMIs associated with each gene, for a more accurate single
cell characterization (Butler, Hoffman, Smibert, Papalexi, & Satija, 2018; W. Chen et al.,
2018). Several tools have been developed by reusing the bulk RNA-seq quantification
methods and taking into account of the UMIs and cell barcodes information incorporated
in the scRNA-seq protocols. Similar to bulk RNA-seq, scRNA-seq involves mapping read
to the reference genome and assign mapped reads to gene features.
The first challenge in scRNA-seq analysis is the amount of data that need to be
processed. A single cell experiment generates 106 ~ 1010 reads for 103 ~ 106 cells

(Svensson, Vento-Tormo, & Teichmann, 2018). Current methods for scRNA-seq analysis

are mainly based on existing bulk RNA-seq tools for read mapping and assignment, with
extended functions for UMI and cell barcode processing. Cell Ranger (Zheng et al., 2017),
a toolkit developed by the commercialized scRNA-seq company 10X Genomics, is the
gold standard to analyzed data generated by 10X Genomics Chromium library. It takes the
paired-end FASTQs as input, extracts UMIs and cell barcodes for Read1 and aligns Read2
to the reference genome using STAR (Bohnert et al.) aligner. Customized python scripts
are provided for UMI/cell barcode correction, UMI deduplication, and UMI counting. Cell
Ranger only counts reads that are confidently mapped to the exonic regions with valid
UMIs and cell barcodes. zUMIs (Parekh, Ziegenhain, Vieth, Enard, & Hellmann, 2018)
first filters reads with low-quality cell barcodes and UMIs and then mapped the rest of the
reads to the genome using STAR (Bohnert et al.) (default setting) or other user-defined
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mappers. It uses featureCounts (Liao et al., 2014) to summarize reads mapped to both exon
and introns and then output the count table with UMI and cell barcode information to R to
summarize read count. UMI-tools (Smith, Heger, & Sudbery, 2017) uses BWA to map
reads to the reference transcriptome and only counts exonic reads. However, as read
mapping is computationally heavy, the alignment-based methods do not scale well with the
large number of cells that may be predicted. For example, Cell Ranger takes 31 hours to
process 784M reads in the 8K PMBCs including around 8,000 cells.
Another challenge in scRNA-seq data analysis is the scRNA-seq specific bias
including 5’- or 3’- end read bias and low sequencing coverage in many of the dropletbased or well-based protocols. During the library preparation, full-length mRNA sequences
are processed for enzymatic fragmentation. It produces transcript fragments with different
sizes. However, in the process of PCR amplification, the primers only recognize fragments
that contains the oligo sequences added with primer sequences for sequencing. So only the
5’ or 3’ portion of the transcript is retained after mRNA fragmentation (Klein et al., 2015;
Macosko et al., 2015; Zheng et al., 2017). The alignment-free methods rely heavily on
transcript coverage information to infer the likelihood of the transcripts of origin for each
read (Bray et al., 2016) (Patro et al., 2017). The resulting library will only produce reads
that are mapped to the first or the last exon of the gene, leading to biased gene body
coverage (Ma et al., 2019). For transcripts differ primarily on the 5’ or 3’ end, accurately
determination the transcripts of origin is difficult. Additionally, average read coverage
from existing scRNA-seq protocols is low, around 50, 000 reads per cell. The low
sequencing depth per cell results in reduced sensitivity for resolving transcript-level
conflicts. Therefore, the 5’/3’-end read bias as well as the low read coverage in scRNA-
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seq make transcript-level quantification even harder due to the reduced information to infer
the transcripts of origin in the alignment-free algorithms. Recently benchmarking study
has shown that alignment-free algorithms report method-specific artifacts and variances in
the number of cells and genes detected. For example, Kallisto detects highly expressed
genes in the Vmn and Olfr families in several of the 10X Genomics datasets, where such
genes are known to be not expressed in the tissues.
The third challenge in scRNA-seq analysis is to appropriately handle scRNA-seq
specific information in the UMI and cell barcode sequences. Due to the small amount of
RNA within each cell, a PCR amplification step is necessary to produce enough cDNA for
the sequencing step. The amplification bias can be corrected computationally in the
downstream analysis using the UMI sequences. If reads with the same UMI sequences from
the same cell are mapped to the same transcript sequence, we can conclude that they are
technical duplicates from PCR amplification and should be collapsed. However,
sequencing errors in the UMIs result in artefactual UMIs inflating the UMI counts (Smith
et al., 2017). Existing methods include UMI correction step to identify multiple similar
UMI sequences and treat them as instances of the same UMI. Cell Ranger, zUMIs and
scPipe (Tian et al., 2018) uses a greedy algorithm comparing each UMI sequence to
identify UMIs within certain hamming distance and collapse them to the higher count UMI.
UMI-tools links UMIs by a single edit distance and aims to reduce the UMI network into
a representative UMI. Salmon constructs a UMI graph to find a minimal set of transcripts
for UMI deduplication (Srivastava, Malik, Smith, Sudbery, & Patro, 2019). Kallisto, on
the other hand, does not perform UMI correction, and uses a naïve method to collapse reads
that contain the same UMI. The sequencing process also introduces errors in cell barcodes.
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Therefore, the correction of errors in cell barcodes is important in cell identification. Cell
Ranger, zUMIs and Kallisto first compares the sequenced barcodes to a whitelist which
contains the pre-defined barcodes in the library preparation kit. If a cell barcode is not in
the whitelist but is 1-hamming distance away from a barcode in the whitelist, it will be
corrected to the corresponding barcode from the whitelist. Salmon generates a putative
whitelist by analyzing the cumulative distribution of barcode frequencies. UMI-tools only
selects cell barcodes in the given whitelist. The various combinations of different read
mappers, criteria of read assignments and UMI+cell barcode handling have big impact on
the gene expression quantification rendering inconsistency in expression differences
detection, cell clustering and trajectory analysis (Simonsen et al., 2018; Tian et al., 2019).
4.2

FastCount algorithm
Despite the existence of large number of tools for bulk and scRNA-seq gene

quantification, these methods face the following challenges: existing methods do not scale
well for large data set especially in the application for the single cell experiment where
millions of reads are sequenced for a single sample; the alignment-free methods are
sensitive to the sequencing read depth and gene body coverage; and the alignment-free
methods provide at least 4 times speed improvement but with the tradeoff for accuracy.
Therefore, we present FastCount, an alignment-free approach to directly assign
read to gene-level features. FastCount skips the computationally intensive read mapping
step and assign reads directly to genes of origin based on the gene-specific 𝑘𝑘 -mers
information. We hypothesize that using gene-specific 𝑘𝑘-mers information simplifies the

gene-level read assignment problem than transcript-specific information and improves the
performance in terms of speed and accuracy.
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FastCount is capable of alignment-free supports alignment-free UMI count
summarization for scRNA-seq data and gene count quantification for bulk RNA-seq data
leveraging gene-specific k-mers. Different from the alignment-based algorithms that
include a computationally intensive read mapping step, FastCount assigns an RNA-seq
read directly to the potential gene based on its k-mer origin information. FastCount uses a
novel data structure, GeneOthello, to assign reads to the corresponding gene identifiers
sharing approximately the same set of k-mers. It conducts read count in a gene without
necessitating detailed read alignment information. FastCount is implemented to handle
UMI and cell barcode information specific to scRNA-seq data, allowing a speedy
assessment of scRNA-seq cell distribution using raw sequencing reads. We demonstrate
through experiment that FastCount scRNA-seq application using 10X Genomics data and
compare the performance to 10X Genomics' toolkit, Cell Ranger. FastCount is over an
order of magnitude faster than Cell Ranger with very competitive accuracy. We also
demonstrate that FastCount is about two orders of magnitude faster than the gold standard
bulk RNA-seq tool, RSEM while achieves competitive accuracy.
4.2.1

Gene 𝑘𝑘-mers signatures

The term "gene count" typically refers to the number of reads sequenced in each
gene within a given RNA-seq sample. Calculating gene count requires assigning each read
to the gene it is sequenced from. Unlike read alignment, read assignment does not require
high resolution base-by-base continuous matching between the read sequence and genomic
reference. Instead, read assignment can be simplified to the identification of the gene that
best matches the set of k-mers present in the read. When k = 21, the majority of k-mers
(93.9% in GRCh38) are unique to the genes carrying them (Figure 16). Therefore, the gene-
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specific k-mers may serve as signatures for read classification problem. The rest of the kmers (6.1% in GRCh38) appear in more than one gene. FastCount leverages this property
and turns gene count into a read assignment problem.
The first step of FastCount method is to establish a mapping between k-mers and
genes. The k-mers in RNA-seq are expected to be from mRNA transcriptome although
these can be expanded to include other RNA species as well. Therefore, we extract all the
k-mers present in the transcript sequences of each gene. These k-mers 𝑆𝑆 are divided into

two categories: gene-specific k-mers and gene-clique k-mers. Each of the gene-specific k-

mers can uniquely identify one gene. Each of k-mers in a gene clique set is not unique to a
gene and instead, is shared by a set of genes, which we refer to as a gene clique. Those kmers are often a result of repetitive sequences but provide useful information on handling
reads that map ambiguously to multiple genes. Thus, we would like to establish a mapping
between the set of transcriptome k-mers and their associated gene features. a). Formally,
let 𝐺𝐺 be genes corresponding to gene-specific k-mers and 𝐶𝐶 be the set of gene cliques. Let

𝐹𝐹 be a feature set containing genes in 𝐺𝐺 and gene cliques in 𝐶𝐶, where 𝐹𝐹 = 𝐺𝐺 ∪ 𝐶𝐶 and
𝐺𝐺 ∩ 𝐶𝐶 = 0 Thus, there exists a many-to-one mapping between 𝑆𝑆 ⟶ 𝐹𝐹 , such that
𝑚𝑚(𝑠𝑠) = 𝐹𝐹.
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Figure 16. Cumulative 𝑘𝑘 -mer percentage at different 𝑘𝑘 -mer occurrence from Human
reference genome GRCh38.
4.2.2

GeneOthello 𝑘𝑘-mers index

The efficiency of gene count procedure relies on how fast one can quickly map a
read to a gene. In our case, it is translated to how fast we can map a k-mer to a gene. To
this end, we have adopted a hashing classifier, called Othello (Yu, Belazzougui, Qian, &
Zhang, 2018), to facilitate the mapping between k-mers and the features 𝑆𝑆. Othello is a

minimal perfect hashing algorithm (MPH) that provides key-to-value query in constant
time. The othello algorithm has demonstrated great scalability in both memory and query
speed in several Bioinformatics applications (Liu et al., 2018; Yu, Liu, et al., 2018).
We build an index, named GeneOthello, in order to store the many-to-one mapping
between the aforementioned transcriptome k-mers and gene features. We encode gene
features 𝐹𝐹 as a set of l-bit integers 𝑉𝑉 = {0, 1 , 2, … , |G|, |G| + 1, |G| + 2, … , |G| + |C|},
where 0 is specially allocated for k-mers with occurrence > n and 𝑙𝑙 = ⌈𝑙𝑙𝑙𝑙𝑙𝑙_2(|𝐹𝐹| + 1)⌉.
GeneOthello O(S, V) maps the predefined set of k-mers S to the gene features in V. Let T ∶
S → V be the function that maps k-mers to the gene features in V, where T(k) indicates the
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feature of a k-mer s ∈ S. GeneOthello maintains a query function τ: U → I that maps the
universal set of k-mers, U (i.e., U = θk , θ = {A, G, C, T}) to the set of all l-bit integers, I =

{0,1, … , 2l − 1}. Therefore, S ⊂ U and V ⊂ I. GeneOthello has the following properties:

1) given a k-mer s ∈ S, a GeneOthello querying τ(s) guarantees returning the correct gene

feature id v; 2) for any alien k-mers, s ′ ∉ S , GeneOthello has a higher probability to assign

s' to a dummy feature τ(s′ ) ∈ I − V than a false positive feature 𝜏𝜏(𝑠𝑠 ′ ) ∈ V (Yu, Liu, et al.,

2018).

The GeneOthello structure includes a pair of hash function ⟨ha , hb ⟩ and two arrays

of l-bit integers A and B. The hash functions and the content of the integer arrays are

precomputed during GeneOthello construction. The hash functions provide the mapping
between the universal k-mer set and the corresponding index location in A and B, that is
ha : U → {0,1, … , ma − 1} and

hb : U → {0,1, … , mb − 1} . A query of a k-mer s on

GeneOthello will first yield indices ha (s) and hb (s) . The feature τ(s) of k-mer s is

computed by the integer values at A[ha (s)] and B[hb (s)] as τ(s) = A[ha (s)] ⨁ B[hb (s)].
The procedure only accesses two memory locations in A and B and a bitwise XOR
operation, making the query execution extremely fast.
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Figure 17 A toy example illustrating FastCount algorithm. The construction of
GeneOthello index from the reference gene sequences. In this example, k-mers (k = 3) in
the reference set are extracted from each reference transcript. Their occurrences within
genes are tabulated and are categorized into gene signatures and cliques (Top). A
GeneOthello index is constructed to store the many to one mapping between the k-mers
and the gene feature indices (Bottom).
4.2.3

Read assignment to genes
One of the key steps in bulk and single cell RNA-seq analysis is to accurately assign

read to the correct gene feature. To do this, FastCount first decomposes read into
consecutive k-mers (Figure 18 Read assignment procedure. k-mers in a read are extracted
and queried against GeneOthello to obtain their gene features. Continuous k-mers with the
same gene feature are clustered into feature windows. The gene assignment of a read is
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determined by the gene that dominates the longest feature window.) and each k-mer is
queried against the GeneOthello index to retrieve its gene feature. Ideally, the read
assignment is straightforward when all k-mers pointing to the same gene. However, this
process is often complicated by the presence of alien k-mers that are absent from the
reference transcriptome. Alien k-mers can be a result of system artifacts during the RNAseq library preparation and sequencing, contamination or novel transcript isoforms (Levy
et al., 2007; Taub, Corrada Bravo, & Irizarry, 2010). When querying on alien k-mers,
majority of them can be easily detected using the dummy features returned by GeneOthello.
But in the cases that an alien k-mer is falsely allocated to a reference gene feature, failure
of detecting it may lead to a false positive read assignment.
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Figure 18 Read assignment procedure. k-mers in a read are extracted and queried against
GeneOthello to obtain their gene features. Continuous k-mers with the same gene feature
are clustered into feature windows. The gene assignment of a read is determined by the
gene that dominates the longest feature window.
FastCount tackles the challenge of alien k-mers using the following strategies: 1)
when constructing GeneOthello index, we intentionally expand the size of I such that many
alien k-mers are categorized into a group that is not overlapping with any valid
transcriptome features I - V. Given the predefined V, we can increase the probability of an
alien

k-mer

falls

in

I

-

V

by

increasing

l,

that

is

2l − |V|
2l

(Liu et al., 2018). 2) in the case that an alien k-mer is falsely assigned to the existing gene
features, we require the presence of at least two consecutive k-mers returning the same
gene feature to be considered as a feature segment for gene assignment. As the indices
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queried by alien k-mers are random, the chance of seeing the same gene assignment from
the two different alien k-mers is very low (Liu et al., 2018).
FastCount performs read assignment with the following procedure: 1) it iterates
through each k-mer along the read to retrieve its gene feature by querying against the
GeneOthello index. With the presence of alien k-mers, gene features along the reads may
be divided into section. We merge continuous gene features into feature segments and
reject the dummy features from alien k-mers. Each feature segment is weighted by the wj =

d2j , where dj is the number of k-mers in the feature segment j, to take into account of the kmer spatial information on the read. 2) We filter feature segments with length < 2 from

feature assignment to remove the possible alien k-mers query falsely return to the known
features. 3) Gene segments are then ranked by the weights to identify the most dominant
feature. 4) The rest of the feature segments are compared to the dominant feature. If there
are no consensus gene feature among the segments, the read is removed from the
assignment; if they all indicate a single consensus gene, the read is assigned to the gene
feature; if they indicate to a set of genes, the case of multi-mapping read, we will not
include this read for feature assignment.
4.2.4

FastCount scRNA-seq implementation
In scRNA-seq analysis, another key step is to appropriately handle the single-cell

specific information in the cell barcode and UMI sequence. FastCount accepts sequencing
FASTQ files that are expected to contain cell barcode and UMI information in one of the
read files and the gene identity file in another. For example, a typical read 10X Genomics
Chromium data is in the form of read pairs, read1 and read2 (Figure 19 Individual barcode
identification and gene assignment for a paired-end read.). Read1 is the cell barcode
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sequence that is used to tag the cell origin of the cDNA followed by the UMI sequence
which labels the cDNA molecule. Read2 is the sequenced nucleotide bases from the cDNA
segment used to determine the gene identity. FastCount algorithm integrates read prefiltering, read assignment, UMI correction and UMI counting steps.

Figure 19 Individual barcode identification and gene assignment for a paired-end read.
FastCount first removes read pairs with invalid CELL BARCODE or UMI sequences using
read1. If read1 corresponds to valid CELL BARCODE and UMI barcodes, it proceeds to
assign read2 to gene features using FastCount read assignment algorithm.
FastCount first filters the low-quality cell barcode and UMI sequences. Due to
potential sequencing and amplification errors in the cell barcode and UMI sequences, the
number of detected cells and UMI counts are usually inflated. FastCount parses the cell
barcode and UMI from the read1 and looking for any "N" bases. Read pairs with 'N's in
either cell barcode or UMI will be skipped for the read assignment step. Cell
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barcode+UMIs pass this filter will be further compared against the cell barcode whitelist
which is the full list of all known cell barcode sequences that are available for cell tagging
during the library preparation. Cell barcodes that more than 1-hamming distance apart from
the whitelist are considered invalid. Otherwise, the reads with valid cell barcode+UMI
sequences are assigned to its potential gene features based on its k-mers information using
the FastCount read assignment algorithm.
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Figure 20 Cell-level feature summarization. Our method iterates through all the read pairs
for gene-level assignment and keeps track of the number of reads assigned to each gene
feature for individual cells using a CELL BARCODE+UMI counts matrix. It then corrects
UMIs based on the UMI counts and UMI sequence differences for each gene feature. The
final feature-barcode matrix summarizes the number of unique UMIs for each gene feature
in each cell.
FastCount keeps tracking the association between the UMIs and gene features for
each individual cell and stores the UMI counts in a cell barcode+UMI counts matrix. After
iterating through all the reads for the feature assignment, FastCount will try to further
mitigate errors in UMIs using the cell barcode+UMI counts information (Figure 20 Celllevel feature summarization. Our method iterates through all the read pairs for gene-level
assignment and keeps track of the number of reads assigned to each gene feature for
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individual cells using a CELL BARCODE+UMI counts matrix. It then corrects UMIs
based on the UMI counts and UMI sequence differences for each gene feature. The final
feature-barcode matrix summarizes the number of unique UMIs for each gene feature in
each cell.). The UMI correction is performed per cell per gene feature. FastCount compares
one UMI against the rest of UMIs under the same gene feature within each cell looking for
the ones that are 1-hamming distance apart. An UMI with lower count is corrected towards
the higher count UMI. The UMI corrected counts matrix then undergoes UMI
deduplication to group duplicate UMIs and collapse them into a single consensus one.
Finally, FastCount counts the number of unique UMIs for each gene-level feature in each
individual cell and reports the feature-barcode matrix in the Market Exchange Format for
downstream analysis.
4.3

Experimental results
We assess the performance of FastCount on bulk RNA-seq and scRNA-seq data

analysis separately. In order to benchmark its performance on bulk RNA-seq data, we
generate a set of simulated data and compare the gene count reported by FastCount to the
ground truth. For scRNA-seq, datasets published by 10X Genomics are selected as
reference sets. The feature-barcode matrix quantified by the standard 10X data analysis
pipeline, CellRanger, is used as the ground truth to evaluate the accuracy measurement.
4.3.1

Bulk RNA-seq simulation datasets
We benchmark the performance of FastCount on bulk RNA-seq using simulated

data generated by rsem-simulate-reads program from RSEM (B. Li & Dewey, 2011). The
parameterization of the dataset is learned from real data sets following the procedure used
in Kallisto(Bray et al., 2016). Specifically, rsem-calculate-expression was run on
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NA12716_7 from the GEUVADIS RNA-seq data to learn the model parameters from the
real data. We simulated 20 different data sets with 30 million 75 bp paired-ends reads using
rsem-simulate-reads. The gene-level expression estimations reported by this program for
each simulation set are used as the true expression levels. We calculated the pearsons and
spearmans correlation values between the estimated abundance and the ground truth. We
further measure the accuracy using median relative difference (MRD) (Bray et al., 2016)
and 5% error fraction (EF) (B. Li & Dewey, 2011) statistics.
4.3.2

scRNA-seq 10X Genomics datasets
Due to the lack of ground truth scRNA-seq dataset, our evaluation focuses on the

scRNA-seq data produced using the widely accepted 10X Genomics Chromium platform.
The filtered feature-barcode matrix quantified by count function in the Cell Ranger pipeline
is used as the reference dataset. We compare how well each tested method correlates with
Cell Ranger's UMI counting results. We include six datasets to exam the performance of
the different tools in terms of different species, tissue types, sequencing depth and library
chemistry. Datasets pbmc_1k_v3 and pbmc_10k_v3 were derived from human peripheral
blood mononuclear cells (PBMCs) and were prepared using the 10X Chromium v3
chemistry. We also include heart_1k_v3 and heart_10k_v3 which are cells from whole
heart of an E18 mouse. Additionally, pbmc4k and pbmc8k are chosen to evaluate the
performance on data generated by 10X Chromium v2 chemistry. The number of cells in
these datasets ranges from ~ 1,000 to ~ 8,000 per sample. They were processed by 10X
Genomics using the standard Cell Ranger pipeline. The raw sequencing FASTQ files are
analyzed by each tool using the recommended settings. The resulting feature-barcode
matrices are compared with the reference datasets quantified by Cell Ranger count to
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evaluate the concordance in gene- and cell-level expression as well as in the downstream
biological inference.
4.3.3

Comparison with other bulk RNA-seq tools
We evaluate FastCount's performance in terms of accuracy and scalability on

analyzing traditional bulk RNA-seq data. We compare its performance with three popularly
used gene count pipelines: STAR (Dobin et al., 2013) in quantMode, featureCounts (Liao
et al., 2014) (STAR aligner) and the gold standard RSEM (B. Li & Dewey, 2011) (STAR
aligner).
STAR was run in 1-pass mode with "quantMode" option enable to summarize the
number of reads assigned per gene during the mapping procedure. featureCounts was run
on the BAM file generated from STAR output and the General Transfer Format (GTF) file
to summarize the read counts on the gene level features. RSEM was run with STAR aligner
and the gene level expression estimates was used for the comparison. All the tools are ran
using their default settings.
For each of the simulated data, we quantify the gene abundances with the four tested
methods and measure the accuracy of gene count estimates. Table 5 Accuracy of gene
count quantification in terms of Pearson and Spearman correlation, MRD and 5% EF using
simulated data. shows the median values of the Pearson, Spearman, MRD and 5% EF for
each of the tested methods using the 20 simulated bulk RNA-seq data. In general,
FastCount achieves a competitive and sometimes slightly better performance over the set
of gene count tools in comparison. FastCount outperforms STAR 1-PASS and
featureCount+STAR pipelines. One major reason for the lower performance in the two
STAR related methods is likely due to that STAR and fetureCount do not handle read
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mapped to multiple gene features. Such reads are dropped from gene counting. RSEM, on
the other hand, uses the Expectation Maximization (EM) algorithm to estimate the
abundance based on the uniquely aligned reads and multi-mapped reads. In FastCount,
multi-mapped reads are allocated to genes in proportion to the gene count quantified using
uniquely-mapped reads.
Table 5 Accuracy of gene count quantification in terms of Pearson and Spearman
correlation, MRD and 5% EF using simulated data.

We then measure the speed and memory usage of FastCount on bulk RNA-seq. All
the pipelines are run on a 16-core Intel Xeon E5-2670 @ 2.60 GHZ Linux server with 64
GB of RAM using 10 threads. FastCount is approximately an order of magnitude faster
than STAR 1-PASS and featureCounts+STAR and is about 2 orders of magnitude faster
than RSEM+STAR (Figure 21 Speed and memory usage of FastCount and 3 other
pipelines : RSEM+STAR, featureCounts+STAR and STAR 1-PASS mode on the 20
simulated data sets. (a) Total runtime for processing all the 20 simulation datasets. (b)
Median peak memory requirement.). Additionally, FastCount requires a maximum of 1.3
GB of memory while any other pipelines requiring about 30GB memory due to the
dependency of STAR alignment.

101

Figure 21 Speed and memory usage of FastCount and 3 other pipelines : RSEM+STAR,
featureCounts+STAR and STAR 1-PASS mode on the 20 simulated data sets. (a) Total
runtime for processing all the 20 simulation datasets. (b) Median peak memory requirement.
4.3.4

Comparison with other scRNA-seq pipelines
We assess the accuracy of FastCount in scRNA-seq quantification and compare its

performance to Cell Ranger, Salmon-Alevin (Srivastava et al., 2019) and Kallisto (Bray et
al., 2016). To make the evaluation comparable to Cell Ranger, we download the reference
packages provided by 10X Genomics for human and mouse samples. We then subset the
GENCODE (Frankish et al., 2019) transcript sequence files for either species (human
GRCh38.p12 release 30, mouse GRCm38.p6 release M21) with the same set of transcripts
used by CellRanger. The common transcripts are used to construct the reference indices
for FastCount, Kallisto and Salmon-Alevin.
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Table 6 UMI count concordance between different methods and Cell Ranger in terms of
median Pearson, Spearman and MRD for the 6 datasets.

Each of the six datasets is processed using default settings by the tested algorithms
to generate the raw feature-barcode matrix. We then subset this matrix to keep the same
set of features and cells reported by Cell Ranger. The filtered matrix is then compared
against the reference Cell Ranger results.
We first calculate the gene-level correlation of the UMI counts for each gene across
all cells between the tested algorithms and Cell Ranger count using the pearson's
correlation, spearman's correlation and median relative difference (MRD) statistics per cell
(Table 6 UMI count concordance between different methods and Cell Ranger in terms of
median Pearson, Spearman and MRD for the 6 datasets.). The results indicate that
FastCount shows the highest degree of agreement to the reference results in all datasets
(median pearson's correlation = 0.998, spearman's correlation = 0.973 and MRD = 0.033).
In comparison, Alevin and Kallisto show a less degree of concordance with cell ranger
especially with scRNA-seq from heart tissues.
We next examine the correlation on cell-level expression in total UMI counts
between the tested algorithms and Cell Ranger. We calculate the total mRNA abundance
within each cell by the sum of the UMI counts for each expressed gene in a cell. The
correspondence in the total UMI counts per cell between the tested methods and Cell
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Ranger is presented in Figure 22 The scatter plots of the total number of UMI counts per
cell. We see high agreements between the three alignment-free methods and Cell Ranger
with points centered around the diagonal line in the scatter plots. FastCount has the highest
degree of concordance in all the six tested datasets, while the total UMI counts by Alevin
and Kallisto show larger variations from the Cell Ranger reference results. Kallisto
consistently overestimates the total gene expression level in the cells. We also observe that
many low-expressed cells in the two mouse heart tissue datasets (heart_1k_v3 and
heart_10k_v3) are missing in Alevin while they are all identified by FastCount, Kallisto
and Cell Ranger count. These findings agree with the benchmark paper reported by
(Brüning, Tombor, Schulz, Dimmeler, & John, 2021).
We further assess the cell-level concordance by calculating the pearson's
correlation in the UMI count of the same cell between the tested methods and Cell Ranger.
We plot the density of the correlation coefficient as a function of total UMI counts per cell
in Figure 23 Pearson correlation of UMI counts within each cell as a function of total UMI
counts per cell. Each point represents a cell and the points are colored based on the number
of neighboring points indicating the overall distribution of the correlation. The pearson's
correlation in the cell-level UMI counts between FastCount and Cell Ranger clustered into
a much narrower range and most of the cells have correlation coefficiency close to 1. In
contrast, many cells show relatively lower correlation in Alevin and Kallisto indicated by
the much more spread-out points on the graphs.
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Figure 22 The scatter plots of the total number of UMI counts per cell between Cell Ranger
and each of the tested algorithms (FastCount, Salmon and Kallisto) from the six 10X
Genomics scRNA-seq datasets.

Figure 23 Pearson correlation of UMI counts within each cell as a function of total UMI
counts per cell using the six 10X Genomics scRNA-seq datasets.
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Figure 24 Compatible t-SNE plots using the feature-barcode matrices generated by Cell
Ranger, FastCount, Kallisto and Salmon for the six 10X Genomics scRNA-seq datasets.
Lastly, to evaluate the the impact of the different cell gene count tools on
downstream cell clustering analysis. We perform dimensionality reduction using tDistributed Stochastic Neighbor Embedding (t-SNE) for each dataset using scater package
{McCarthy, 2017 #752}. Figure 24 Compatible t-SNE plots using the feature-barcode
matrices shows that the t-SNE plots from Cell Ranger and FastCount are very similar
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across all six data sets, retaining all the clustering structures and embedding shapes. In
contrast, the distribution of clusters varies significantly using Alevins and Kallisto cell
count results. The difference becomes more apparent when the composition of clusters is
complex.
4.3.5

Runtime comparison
We benchmark the runtime used for each algorithm using the six testing datasets.

All methods are evaluated on a 16-core Intel Xeon E5-2670 @ 2.60 GHZ Linux server
with 64 GB of RAM using 10 threads. The result is shown in Table 7 Runtime comparison
on 10X Genomics single cell gene expression datasets in different tools. In general,
FastCount is at least 1.5 orders of magnitude faster than Cell Ranger count. For example,
FastCount used only 4.1 minutes to process 1K PBMCs data set which contains around
1000 cells and 66 million of reads, while Cell Ranger took 154.2 minutes. For 8K PBMCs
which contains around 8000 cells and 784 million of reads, FastCount used only 46.5
minutes, while Cell Ranger needed 31 hours. FastCount is around 3 times faster than
Alevin except for the 2 mouse heart samples. This is because Alevin pre-filtered many
(25.6% in 1K Heart, 26.8% in 10K Heart) cells before the read assignment and UMI
quantification steps which largely reduced the number of reads required for processing.
This pre-filtering step resulted in many cells missing from the final expression matrix.
Kallisto is the fastest algorithm but the runtime between FastCount and Kallisto is quite
close.
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Table 7 Runtime comparison on 10X Genomics single cell gene expression datasets in
different tools

4.4

Conclusion
In this chapter, we present FastCount, a novel alignment-free approach to quantify

gene count in individual cells with scRNA-seq data. Comparing to the other alignmentfree algorithms, FastCount shows a higher degree of concordance with Cell Ranger's
cellranger count in both cell-level and gene-level expression, in the meantime provides
1.5 orders of magnitude speed improvement over Cell Ranger.
FastCount assigns sequencing reads directly to genes using gene-specific and geneclique k-mers. It fully utilizes the cell barcode and UMI information in the sequencing
reads to computationally allocate reads to the cells of origin while identifying technical
artifacts from PCR amplification. We evaluate the accuracy of FastCount on scRNA-seq
quantification using the results reported by Cell Ranger as the reference data sets. We
observe that different quantification pipeline implementation influences the single cell
experiment qualities in terms of genes/cells expression level and the downstream
analysis.
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The read processing step of scRNA-seq data is the first and most fundamental step
during the scRNA-seq analysis pipeline. However, the commonly used Cell Ranger count
often requires many hours of CPU times and extensive resources that are only available
to computational servers. Being capable of processing 1,000 cells under 5 minutes on a
regular laptop, Fastcount provides a lightweight but fast alternative, making it possible to
combine cell count together with downstream analysis such as Seruat or Scanpy in one
pipeline.
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CHAPTER 5. Conclusion
Cancer research is in the genomics era. Large-scale cancer genomics research has
been focusing on comprehensive characterization of the cancer landscape using massive
production of genomic, transcriptomic, epigenomic, and proteomic data. Bioinformatics
methods have become one of the key components in cancer study that transform the
sequencing reads generated by various Next Generation Sequencing assays into
information that is interpretable by the biologist. Accurate analysis of NGS data is a critical
step upon which virtually all downstream interpretation process relies. Despite an active
research field in the past decade, existing methods are still facing the challenge of high
complexity and weakness in performance. This dissertation presents three novel
computational methods for developing robust and reproducible NGS pipeline platform,
efficient genome-wide driver mutation identification algorithm and alignment-free
quantification algorithm for bulk RNA-seq and single cell RNA-seq .
In the second chapter of the dissertation, I developed a robust, reproducible and
scalable Bioinformatics pipeline framework that streamlines the DNA sequencing analysis
workflow for cancer genomic mutation identification. It automates the best practice
mutation calling pipelines to detect somatic single nucleotide polymorphisms, indels and
copy number variation from DNA sequencing data and perform various downstream
analyses. It integrates mutation annotation, clinically actionable therapy prediction and
data visualization that simplifies the sequence-to-report data transformation. It has been
applied to the real-world data that characterizes the genomic landscape of squamous cell
lung cancer from Appalachian Kentucky using whole exome sequencing data. It is the first
sequencing effort that provides an overview of the somatic alterations and copy-number
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variations, explores unique mutational patterns comparing to the TCGA cohorts, and
indicates clinically actionable assessment of mutations in this population.
Large-scale sequencing efforts identify thousands of somatic mutations from
cancer samples. Differentiating the driver mutations among a vast pool of passenger
mutations is an important but challenging task in cancer research. In the third chapter, I
developed MEScan, which is one of the first method that enables genome-scale driver
mutations identification based on mutual exclusivity test using cancer mutation data.
MEScan implements an efficient statistical framework to de novo screen mutual exclusive
patterns and in the meantime taking into patient-specific and gene-specific background
mutation rate and adjusting the heterogenous mutation frequency. It outperforms several
existing methods based on simulation studies and is at least 2-fold of magnitudes faster
than most of the tools. MEScan implements a Markov chain Monte Carlo (MCMC)
algorithm to efficiently scan for mutually exclusive gene sets at the genomic scale, a false
discovery rate (FDR) adjustment procedure to control false positives, and a summarization
procedure to select high-confidence findings. Genome-wide screening using existing
TCGA somatic mutation data discovers novel cancer-specific and pan-cancer mutually
exclusive patterns.
Recent advances in scRNA-seq technology allows cancer biologists to appreciate
heterogeneous gene expression changes on the cellular level. scRNA-seq data processing
using current methods is computationally challenging due to the volume of the data
generated in a single cell experiment as well as the single cell specific information carried
in the reads. In the fourth chapter, I designed and implemented a light-weight RNA-seq
read classification algorithm based on gene-specific k-mers in the transcriptome. It
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provides comparable accuracy to the current gold standard algorithm, but achieves around
two orders of magnitude speed improvement. I further extended this read classification
algorithm for single cell RNA-seq quantification by incorporating the cell barcode and
UMI information. It quantifies 800 Million reads of 8,000 cells in less than 50 minutes
which is over an order-of-magnitude faster than the classic 10X Genomics Cell Ranger (31
hours) workflow while providing competitive accuracy in terms of UMI counts, cell
clustering and differentially expressed genes.
Cancer research has become increasingly data centric and relies heavily on the big
data generated from various sequencing assays to interrogate genomic changes using multiOmics data. Cancer Bioinformatics research has become a key component in supporting
the cutting-edge cancer research. Therefore, novel method development in Cancer
Bioinformatics continues to be in high demand driven by novel biomedical applications.
The works presented in this dissertation are expected to resolve some of the fundamental
challenges faced by cancer researchers in analyzing large-scale cancer genomics data.

112

REFERENCES
Adebali, O., Reznik, A. O., Ory, D. S., & Zhulin, I. B. (2016). Establishing the precise
evolutionary history of a gene improves prediction of disease-causing missense
mutations. Genet Med, 18(10), 1029-1036. doi:10.1038/gim.2015.208
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., . . . others.
(2015). Genomic classification of cutaneous melanoma. Cell, 161(7), 1681-1696.
Anders, S., Pyl, P. T., & Huber, W. (2015). HTSeq--a Python framework to work with
high-throughput
sequencing
data.
Bioinformatics,
31(2),
166-169.
doi:10.1093/bioinformatics/btu638
Arita, A., Shamy, M. Y., Chervona, Y., Clancy, H. A., Sun, H., Hall, M. N., . . . Costa, M.
(2012). The effect of exposure to carcinogenic metals on histone tail modifications
and gene expression in human subjects. J Trace Elem Med Biol, 26(2-3), 174-178.
doi:10.1016/j.jtemb.2012.03.012
Avivar-Valderas, A., McEwen, R., Taheri-Ghahfarokhi, A., Carnevalli, L. S., Hardaker, E.
L., Maresca, M., . . . Cruzalegui, F. (2018). Functional significance of co-occurring
mutations in PIK3CA and MAP3K1 in breast cancer. Oncotarget, 9(30), 21444.
Baruzzo, G., Hayer, K. E., Kim, E. J., Di Camillo, B., FitzGerald, G. A., & Grant, G. R.
(2017). Simulation-based comprehensive benchmarking of RNA-seq aligners. Nat
Methods, 14(2), 135-139. doi:10.1038/nmeth.4106
Best, S. A., De Souza, D. P., Kersbergen, A., Policheni, A. N., Dayalan, S., Tull, D., . . .
others. (2018). Synergy between the KEAP1/NRF2 and PI3K pathways drives nonsmall-cell lung cancer with an altered immune microenvironment. Cell metabolism,
27(4), 935-943.
Bianconi, E., Piovesan, A., Facchin, F., Beraudi, A., Casadei, R., Frabetti, F., . . . Canaider,
S. (2013). An estimation of the number of cells in the human body. Ann Hum Biol,
40(6), 463-471. doi:10.3109/03014460.2013.807878
Biterge, B., Richter, F., Mittler, G., & Schneider, R. (2014). Methylation of histone H4 at
aspartate 24 by protein L-isoaspartate O-methyltransferase (PCMT1) links histone
modifications with protein homeostasis. Sci Rep, 4, 6674. doi:10.1038/srep06674
Bohnert, R., Vivas, S., & Jansen, G. (2017). Comprehensive benchmarking of SNV callers
for highly admixed tumor data. PLoS One, 12(10), e0186175.
doi:10.1371/journal.pone.0186175
Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: a flexible trimmer for
Illumina
sequence
data.
Bioinformatics,
30(15),
2114-2120.
doi:10.1093/bioinformatics/btu170
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016). Near-optimal probabilistic
RNA-seq quantification. Nat Biotechnol, 34(5), 525-527. doi:10.1038/nbt.3519
Brennan, C. W., Verhaak, R. G., McKenna, A., Campos, B., Noushmehr, H., Salama, S.
R., . . . Network, T. R. (2013). The somatic genomic landscape of glioblastoma.
Cell, 155(2), 462-477. doi:10.1016/j.cell.2013.09.034
Brüning, R. S., Tombor, L., Schulz, M. H., Dimmeler, S., & John, D. (2021). Comparative
Analysis of common alignment tools for single cell RNA sequencing. bioRxiv,
2021.2002.2015.430948. doi:10.1101/2021.02.15.430948

113

Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013). The causes and
consequences of genetic heterogeneity in cancer evolution. Nature, 501(7467),
338-345. doi:10.1038/nature12625
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018). Integrating singlecell transcriptomic data across different conditions, technologies, and species.
Nature Biotechnology, 36(5), 411-420. doi:10.1038/nbt.4096
Cairns, R. A., & Mak, T. W. (2013). Oncogenic isocitrate dehydrogenase mutations:
mechanisms, models, and clinical opportunities. Cancer Discov, 3(7), 730-741.
doi:10.1158/2159-8290.CD-13-0083
Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., . . .
Meyerson, M. (2016). Distinct patterns of somatic genome alterations in lung
adenocarcinomas and squamous cell carcinomas. Nat Genet, 48(6), 607-616.
doi:10.1038/ng.3564
Cancer Genome Atlas, N. (2012). Comprehensive molecular portraits of human breast
tumours. Nature, 490(7418), 61-70. doi:10.1038/nature11412
Cancer Genome Atlas Research, N. (2011). Integrated genomic analyses of ovarian
carcinoma. Nature, 474(7353), 609-615. doi:10.1038/nature10166
Cancer Genome Atlas Research, N. (2012). Comprehensive genomic characterization of
squamous cell lung cancers. Nature, 489(7417), 519-525. doi:10.1038/nature11404
Cancer Genome Atlas Research, N., Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw,
K. R., Ozenberger, B. A., . . . Stuart, J. M. (2013). The Cancer Genome Atlas PanCancer analysis project. Nat Genet, 45(10), 1113-1120. doi:10.1038/ng.2764
Cao, B., Fang, Z., Liao, P., Zhou, X., Xiong, J., Zeng, S., & Lu, H. (2017). Cancer-mutated
ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking
p53-MDM2 circuit. Oncotarget, 8(53), 90651.
Carbonneau, M. e., lissa, Gagn\'e, Laurence M., Lalonde, M.-E., Germain, M.-A., Motorina,
A., Guiot, M.-C., . . . others. (2016). The oncometabolite 2-hydroxyglutarate
activates the mTOR signalling pathway. Nat Commun, 7, 12700.
Carracedo, A., & Pandolfi, P. P. (2008). The PTEN--PI3K pathway: of feedbacks and
cross-talks. Oncogene, 27(41), 5527.
Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., . . . Schultz, N.
(2017). OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol, 2017.
doi:10.1200/PO.17.00011
Chang, E. C., Anurag, M., Gao, J., Cakar, B., Du, X., Li, J., . . . others. (2018). NF1 as an
estrogen receptor-$$ co-repressor in breast cancer. In.
Chen, W., Li, Y., Easton, J., Finkelstein, D., Wu, G., & Chen, X. (2018). UMI-count
modeling and differential expression analysis for single-cell RNA sequencing.
Genome Biol, 19(1), 70. doi:10.1186/s13059-018-1438-9
Chen, X., Zhang, X.-l., Zhang, G.-h., & Gao, Y.-f. (2019). Artesunate promotes Th1
differentiation from CD4+ T cells to enhance cell apoptosis in ovarian cancer via
miR-142. Brazilian Journal of Medical and Biological Research, 52(5).
Chervona, Y., Arita, A., & Costa, M. (2012). Carcinogenic metals and the epigenome:
understanding the effect of nickel, arsenic, and chromium. Metallomics, 4(7), 619627. doi:10.1039/c2mt20033c

114

Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., . . .
Getz, G. (2013). Sensitive detection of somatic point mutations in impure and
heterogeneous cancer samples. Nat Biotech, 31(3), 213-219. doi:10.1038/nbt.2514
http://www.nature.com/nbt/journal/v31/n3/abs/nbt.2514.html#supplementary-information
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., . . .
Getz, G. (2013). Sensitive detection of somatic point mutations in impure and
heterogeneous
cancer
samples.
Nat
Biotechnol,
31(3),
213-219.
doi:10.1038/nbt.2514
Colombo, E., Marine, J.-C., Danovi, D., Falini, B., & Pelicci, P. G. (2002). Nucleophosmin
regulates the stability and transcriptional activity of p53. Nature cell biology, 4(7),
529.
Colombo, E., Martinelli, P., Zamponi, R., Shing, D. C., Bonetti, P., Luzi, L., . . . others.
(2006). Delocalization and destabilization of the Arf tumor suppressor by the
leukemia-associated NPM mutant. Cancer research, 66(6), 3044-3050.
Conesa, A., Madrigal, P., Tarazona, S., Gomez-Cabrero, D., Cervera, A., McPherson,
A., . . . Mortazavi, A. (2016). A survey of best practices for RNA-seq data analysis.
Genome Biol, 17, 13. doi:10.1186/s13059-016-0881-8
Consortium, I. T. P.-C. A. o. W. G. (2020). Pan-cancer analysis of whole genomes. Nature,
578(7793), 82.
Constantinescu, S., Szczurek, E., Mohammadi, P., Rahnenfuhrer, J., & Beerenwinkel, N.
(2016). TiMEx: a waiting time model for mutually exclusive cancer alterations.
Bioinformatics, 32(7), 968-975. doi:10.1093/bioinformatics/btv400
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., . . .
Su, S. M. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature, 462(7274), 739-744. doi:10.1038/nature08617
Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., . . .
others. (2018). Perspective on oncogenic processes at the end of the beginning of
cancer genomics. Cell, 173(2), 305-320.
Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., . . .
Cancer Genome Atlas Research, N. (2018). Perspective on Oncogenic Processes at
the End of the Beginning of Cancer Genomics. Cell, 173(2), 305-320 e310.
doi:10.1016/j.cell.2018.03.033
Dischinger, P. S., Tovar, E. A., Essenburg, C. J., Madaj, Z. B., Gardner, E. E., Callaghan,
M. E., . . . others. (2018). NF1 deficiency correlates with estrogen receptor signaling
and diminished survival in breast cancer. NPJ breast cancer, 4(1), 29.
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., . . . Gingeras, T.
R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 29(1), 1521.
Efron, B. (2004a). Large-Scale Simultaneous Hypothesis Testing. Journal of the American
Statistical Association, 99(465), 96-104. doi:10.1198/016214504000000089
Efron, B. (2004b). Large-scale simultaneous hypothesis testing: the choice of a null
hypothesis. Journal of the American Statistical Association, 99(465), 96-104.
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., . . .
Campbell, P. J. (2015). COSMIC: exploring the world's knowledge of somatic
mutations in human cancer. Nucleic Acids Res, 43(Database issue), D805-811.
doi:10.1093/nar/gku1075
115

Frankish, A., Diekhans, M., Ferreira, A. M., Johnson, R., Jungreis, I., Loveland, J., . . .
Flicek, P. (2019). GENCODE reference annotation for the human and mouse
genomes. Nucleic Acids Res, 47(D1), D766-d773. doi:10.1093/nar/gky955
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., . . . Stratton,
M. R. (2004). A census of human cancer genes. Nat Rev Cancer, 4(3), 177-183.
doi:10.1038/nrc1299
Goecks, J., Nekrutenko, A., Taylor, J., & Galaxy, T. (2010). Galaxy: a comprehensive
approach for supporting accessible, reproducible, and transparent computational
research in the life sciences. Genome Biol, 11(8), R86. doi:10.1186/gb-2010-11-8r86
Guo, Y., Li, J., Li, C. I., Long, J., Samuels, D. C., & Shyr, Y. (2012). The effect of strand
bias in Illumina short-read sequencing data. BMC Genomics, 13, 666.
doi:10.1186/1471-2164-13-666
Halvorsen, A. R., Silwal-Pandit, L., Meza-Zepeda, L. A., Vodak, D., Vu, P., Sagerup, C., . . .
Helland, A. (2016). TP53 Mutation Spectrum in Smokers and Never Smoking Lung
Cancer Patients. Front Genet, 7, 85. doi:10.3389/fgene.2016.00085
Hamamoto, R., Saloura, V., & Nakamura, Y. (2015). Critical roles of non-histone protein
lysine methylation in human tumorigenesis. Nat Rev Cancer, 15(2), 110-124.
doi:10.1038/nrc3884
Hirano, T. (2006). At the heart of the chromosome: SMC proteins in action. Nature reviews
Molecular cell biology, 7(5), 311.
Hua, X., Hyland, P. L., Huang, J., Song, L., Zhu, B., Caporaso, N. E., . . . Shi, J. (2016).
MEGSA: A powerful and flexible framework for analyzing mutual exclusivity of
tumor mutations. The American Journal of Human Genetics, 98(3), 442-455.
Hua, X., Hyland, P. L., Huang, J., Song, L., Zhu, B., Caporaso, N. E., . . . Shi, J. (2016).
MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity
of
Tumor
Mutations.
Am
J
Hum
Genet,
98(3),
442-455.
doi:10.1016/j.ajhg.2015.12.021
International Cancer Genome, C., Hudson, T. J., Anderson, W., Artez, A., Barker, A. D.,
Bell, C., . . . Yang, H. (2010). International network of cancer genome projects.
Nature, 464(7291), 993-998. doi:10.1038/nature08987
Jeon, Y. W., Kim, R. M., Lim, S. T., Choi, H. J., & Suh, Y. J. (2015). Early-onset breast
cancer in a family with neurofibromatosis type 1 associated with a germline
mutation in BRCA1. Journal of breast cancer, 18(1), 97-100.
Joberty, G., Boesche, M., Brown, J. A., Eberhard, D., Garton, N. S., Humphreys, P. G., . . .
Drewes, G. (2016). Interrogating the Druggability of the 2-OxoglutarateDependent Dioxygenase Target Class by Chemical Proteomics. ACS Chem Biol,
11(7), 2002-2010. doi:10.1021/acschembio.6b00080
Johnson, N., Shelton, B. J., Hopenhayn, C., Tucker, T. T., Unrine, J. M., Huang, B., . . . Li,
L. (2011). Concentrations of arsenic, chromium, and nickel in toenail samples from
Appalachian Kentucky residents. J Environ Pathol Toxicol Oncol, 30(3), 213-223.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22126614
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014). Ovarian cancerassociated mutations disable catalytic activity of CDK12, a kinase that promotes
homologous recombination repair and resistance to cisplatin and poly (ADP-ribose)
polymerase inhibitors. Journal of Biological Chemistry, 289(13), 9247-9253.
116

Kamps, R., Brandao, R. D., Bosch, B. J., Paulussen, A. D., Xanthoulea, S., Blok, M. J., &
Romano, A. (2017). Next-Generation Sequencing in Oncology: Genetic Diagnosis,
Risk Prediction and Cancer Classification. Int J Mol Sci, 18(2).
doi:10.3390/ijms18020308
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., . . . Ding, L. (2013).
Mutational landscape and significance across 12 major cancer types. Nature,
502(7471), 333-339. doi:10.1038/nature12634
Kerins, M. J., & Ooi, A. (2018). A catalogue of somatic NRF2 gain-of-function mutations
in cancer. Sci Rep, 8(1), 12846.
Kim, Y.-A., Madan, S., & Przytycka, T. M. (2017). WeSME: uncovering mutual
exclusivity of cancer drivers and beyond. Bioinformatics, 33(6), 814-821.
Kim, Y., Hammerman, P. S., Kim, J., Yoon, J.-a., Lee, Y., Sun, J.-M., . . . Park, K. (2014).
Integrative and Comparative Genomic Analysis of Lung Squamous Cell
Carcinomas in East Asian Patients. Journal of Clinical Oncology, 32(2), 121-128.
doi:10.1200/JCO.2013.50.8556
Kim, Y. A., Madan, S., & Przytycka, T. M. (2017). WeSME: uncovering mutual
exclusivity of cancer drivers and beyond. Bioinformatics, 33(6), 814-821.
doi:10.1093/bioinformatics/btw242
Klein, A. M., Mazutis, L., Akartuna, I., Tallapragada, N., Veres, A., Li, V., . . . Kirschner,
M. W. (2015). Droplet barcoding for single-cell transcriptomics applied to
embryonic stem cells. Cell, 161(5), 1187-1201. doi:10.1016/j.cell.2015.04.044
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., . . . Wilson,
R. K. (2012). VarScan 2: somatic mutation and copy number alteration discovery
in cancer by exome sequencing. Genome Res, 22(3), 568-576.
doi:10.1101/gr.129684.111
Korthauer, K. D., & Kendziorski, C. (2015). MADGiC: a model-based approach for
identifying driver genes in cancer. Bioinformatics, 31(10), 1526-1535.
doi:10.1093/bioinformatics/btu858
Koster, J., & Rahmann, S. (2018). Snakemake-a scalable bioinformatics workflow engine.
Bioinformatics, 34(20), 3600. doi:10.1093/bioinformatics/bty350
Labbe, R. M., Holowatyj, A., & Yang, Z. Q. (2013). Histone lysine demethylase (KDM)
subfamily 4: structures, functions and therapeutic potential. Am J Transl Res, 6(1),
1-15. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24349617
Langdon, W. B. (2015). Performance of genetic programming optimised Bowtie2 on
genome comparison and analytic testing (GCAT) benchmarks. BioData Min, 8(1),
1. doi:10.1186/s13040-014-0034-0
Lau, J. W., Lehnert, E., Sethi, A., Malhotra, R., Kaushik, G., Onder, Z., . . . Seven Bridges,
C. G. C. T. (2017). The Cancer Genomics Cloud: Collaborative, Reproducible, and
Democratized-A New Paradigm in Large-Scale Computational Research. Cancer
Res, 77(21), e3-e6. doi:10.1158/0008-5472.CAN-17-0387
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., . . .
Getz, G. (2013). Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature, 499(7457), 214-218. doi:10.1038/nature12213
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., . . .
others. (2013). Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature, 499(7457), 214.
117

Lee, J. C., Kang, S. U., Jeon, Y., Park, J. W., You, J. S., Ha, S. W., . . . Han, J. W. (2012).
Protein L-isoaspartyl methyltransferase regulates p53 activity. Nat Commun, 3, 927.
doi:10.1038/ncomms1933
Leiserson, M. D., Reyna, M. A., & Raphael, B. J. (2016). A weighted exact test for
mutually exclusive mutations in cancer. Bioinformatics, 32(17), i736-i745.
doi:10.1093/bioinformatics/btw462
Leiserson, M. D., Wu, H. T., Vandin, F., & Raphael, B. J. (2015). CoMEt: a statistical
approach to identify combinations of mutually exclusive alterations in cancer.
Genome Biol, 16, 160. doi:10.1186/s13059-015-0700-7
Leiserson, M. D. M., Blokh, D., Sharan, R., & Raphael, B. J. (2013). Simultaneous
identification of multiple driver pathways in cancer. PLoS Comput Biol, 9(5),
e1003054.
Leiserson, M. D. M., Reyna, M. A., & Raphael, B. J. (2016). A weighted exact test for
mutually exclusive mutations in cancer. Bioinformatics, 32(17), i736-i745.
Leiserson, M. D. M., Wu, H.-T., Vandin, F., & Raphael, B. J. (2015). CoMEt: a statistical
approach to identify combinations of mutually exclusive alterations in cancer.
Genome biology, 16(1), 160.
Levy, S., Sutton, G., Ng, P. C., Feuk, L., Halpern, A. L., Walenz, B. P., . . . Venter, J. C.
(2007). The diploid genome sequence of an individual human. PLoS Biol, 5(10),
e254. doi:10.1371/journal.pbio.0050254
Li, B., & Dewey, C. N. (2011). RSEM: accurate transcript quantification from RNA-Seq
data with or without a reference genome. BMC Bioinformatics, 12, 323.
doi:10.1186/1471-2105-12-323
Li, C., Gao, Z., Li, F., Li, X., Sun, Y., Wang, M., . . . Wei, Q. (2015). Whole Exome
Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in
Chinese Patients with Lung Squamous Cell Carcinoma. Sci Rep, 5, 14237.
doi:10.1038/srep14237
Li, H. (2011). A statistical framework for SNP calling, mutation discovery, association
mapping and population genetical parameter estimation from sequencing data.
Bioinformatics, 27(21), 2987-2993. doi:10.1093/bioinformatics/btr509
Li, H., & Durbin, R. (2010). Fast and accurate long-read alignment with Burrows-Wheeler
transform. Bioinformatics, 26(5), 589-595. doi:10.1093/bioinformatics/btp698
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., . . . Wang, L. (2016). PI3K/Akt/mTOR
signaling pathway and targeted therapy for glioblastoma. Oncotarget, 7(22), 33440.
Liao, Y., Smyth, G. K., & Shi, W. (2014). featureCounts: an efficient general purpose
program for assigning sequence reads to genomic features. Bioinformatics, 30(7),
923-930. doi:10.1093/bioinformatics/btt656
Little, R. J. A. (1991). Inference with survey weights. Journal of Official Statistics, 7(4),
405.
Liu, X., Yu, Y., Liu, J., Elliott, C. F., Qian, C., & Liu, J. (2018). A novel data structure to
support ultra-fast taxonomic classification of metagenomic sequences with k-mer
signatures. Bioinformatics, 34(1), 171-178. doi:10.1093/bioinformatics/btx432
Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol, 15(12), 550.
doi:10.1186/s13059-014-0550-8

118

Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., . . . Thompson,
C. B. (2012). IDH mutation impairs histone demethylation and results in a block to
cell differentiation. Nature, 483(7390), 474-478. doi:10.1038/nature10860
Ma, F., Fuqua, B. K., Hasin, Y., Yukhtman, C., Vulpe, C. D., Lusis, A. J., & Pellegrini, M.
(2019). A comparison between whole transcript and 3’ RNA sequencing methods
using Kapa and Lexogen library preparation methods. BMC Genomics, 20(1), 9.
doi:10.1186/s12864-018-5393-3
Macosko, E. Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., . . . McCarroll,
S. A. (2015). Highly Parallel Genome-wide Expression Profiling of Individual
Cells
Using
Nanoliter
Droplets.
Cell,
161(5),
1202-1214.
doi:10.1016/j.cell.2015.05.002
Martin, M. (2011a). Cutadapt removes adapter sequences from high-throughput
sequencing reads. 2011, 17(1). doi:10.14806/ej.17.1.200
pp. 10-12
Martin, M. (2011b). Cutadapt removes adapter sequences from high-throughput
sequencing reads. 17(1). doi:http://dx.doi.org/10.14806/ej.17.1.200
McFadden, P. N., & Clarke, S. (1982). Methylation at D-aspartyl residues in erythrocytes:
possible step in the repair of aged membrane proteins. Proc Natl Acad Sci U S A,
79(8), 2460-2464. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/6123997
McGranahan, N., & Swanton, C. (2017). Clonal heterogeneity and tumor evolution: past,
present, and the future. Cell, 168(4), 613-628.
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., . . .
DePristo, M. A. (2010). The Genome Analysis Toolkit: A MapReduce framework
for analyzing next-generation DNA sequencing data. Genome Research, 20(9),
1297-1303. doi:10.1101/gr.107524.110
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., . . .
DePristo, M. A. (2010). The Genome Analysis Toolkit: a MapReduce framework
for analyzing next-generation DNA sequencing data. Genome Res, 20(9), 12971303. doi:10.1101/gr.107524.110
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G.
(2011). GISTIC2.0 facilitates sensitive and confident localization of the targets of
focal somatic copy-number alteration in human cancers. Genome Biol, 12(4), R41.
doi:10.1186/gb-2011-12-4-r41
Meyerson, M., Gabriel, S., & Getz, G. (2010). Advances in understanding cancer genomes
through second-generation sequencing. Nat Rev Genet, 11(10), 685-696.
doi:10.1038/nrg2841
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., . . .
others. (2017). Conditional selection of genomic alterations dictates cancer
evolution and oncogenic dependencies. Cancer cell, 32(2), 155-168.
Modugno, F., Laskey, R., Smith, A. L., Andersen, C. L., Haluska, P., & Oesterreich, S.
(2012). Hormone response in ovarian cancer: time to reconsider as a clinical target?
Endocrine-related cancer, 19(6), R255-R279.
Molenaar, R. J., Thota, S., Nagata, Y., Patel, B., Clemente, M., Przychodzen, B., . . .
Maciejewski, J. P. (2015). Clinical and biological implications of ancestral and nonancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia, 29(11),
2134-2142. doi:10.1038/leu.2015.91
119

Mondesir, J., Willekens, C., Touat, M., & de Botton, S. (2016). IDH1 and IDH2 mutations
as novel therapeutic targets: current perspectives. J Blood Med, 7, 171-180.
doi:10.2147/JBM.S70716
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., . . . others.
(2016). Landscape of somatic mutations in 560 breast cancer whole-genome
sequences. Nature, 534(7605), 47-54.
Okumura, F., Joo-Okumura, A., Nakatsukasa, K., & Kamura, T. (2016). The role of cullin
5-containing ubiquitin ligases. Cell Div, 11, 1. doi:10.1186/s13008-016-0016-3
Paculov\'a, Hana, & Kohoutek, J. v., ,\'\i,. (2017). The emerging roles of CDK12 in
tumorigenesis. Cell Div, 12(1), 7.
Parekh, S., Ziegenhain, C., Vieth, B., Enard, W., & Hellmann, I. (2018). zUMIs - A fast
and flexible pipeline to process RNA sequencing data with UMIs. Gigascience,
7(6). doi:10.1093/gigascience/giy059
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017). Salmon provides
fast and bias-aware quantification of transcript expression. Nat Methods, 14(4),
417-419. doi:10.1038/nmeth.4197
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H.
A., . . . others. (2016). The somatic mutation profiles of 2,433 breast cancers refine
their genomic and transcriptomic landscapes. Nat Commun, 7(1), 1-16.
Petitjean, A., Achatz, M. I., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007). TP53
mutations in human cancers: functional selection and impact on cancer prognosis
and outcomes. Oncogene, 26(15), 2157-2165. doi:10.1038/sj.onc.1210302
Pfeffermann, D. (1996). The use of sampling weights for survey data analysis. Statistical
methods in medical research, 5(3), 239-261.
Philip, B., Diana, X. Y., Silvis, M. R., Shin, C. H., Robinson, J. P., Robinson, G. L., . . .
others. (2018). Mutant IDH1 promotes glioma formation in vivo. Cell reports,
23(5), 1553-1564.
Ramos, A. H., Lichtenstein, L., Gupta, M., Lawrence, M. S., Pugh, T. J., Saksena, G., . . .
Getz, G. (2015). Oncotator: cancer variant annotation tool. Hum Mutat, 36(4),
E2423-2429. doi:10.1002/humu.22771
Rhodes, J. M., Bentley, F. K., Print, C. G., Dorsett, D., Misulovin, Z., Dickinson, E. J., . . .
Horsfield, J. A. (2010). Positive regulation of c-Myc by cohesin is direct, and
evolutionarily conserved. Developmental biology, 344(2), 637-649.
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010). edgeR: a Bioconductor package
for differential expression analysis of digital gene expression data. Bioinformatics,
26(1), 139-140. doi:10.1093/bioinformatics/btp616
Sathirapongsasuti, J. F., Lee, H., Horst, B. A., Brunner, G., Cochran, A. J., Binder, S., . . .
Nelson, S. F. (2011). Exome sequencing-based copy-number variation and loss of
heterozygosity detection: ExomeCNV. Bioinformatics, 27(19), 2648-2654.
doi:10.1093/bioinformatics/btr462
Schoenberg, N. E., Huang, B., Seshadri, S., & Tucker, T. C. (2015). Trends in cigarette
smoking and obesity in Appalachian Kentucky. South Med J, 108(3), 170-177.
doi:10.14423/SMJ.0000000000000245
Schwartz, R., & Sch\"a, f., Alejandro A. (2017). The evolution of tumour phylogenetics:
principles and practice. Nature Reviews Genetics, 18(4), 213.

120

Seyednasrollah, F., Laiho, A., & Elo, L. L. (2015). Comparison of software packages for
detecting differential expression in RNA-seq studies. Brief Bioinform, 16(1), 59-70.
doi:10.1093/bib/bbt086
Sherr, C. J. (2006). Autophagy by ARF: a short story. Molecular cell, 22(4), 436-437.
Simonsen, A. T., Hansen, M. C., Kjeldsen, E., Moller, P. L., Hindkjaer, J. J., Hokland, P.,
& Aggerholm, A. (2018). Systematic evaluation of signal-to-noise ratio in variant
detection from single cell genome multiple displacement amplification and exome
sequencing. BMC Genomics, 19(1), 681. doi:10.1186/s12864-018-5063-5
Smith, T., Heger, A., & Sudbery, I. (2017). UMI-tools: modeling sequencing errors in
Unique Molecular Identifiers to improve quantification accuracy. Genome Res,
27(3), 491-499. doi:10.1101/gr.209601.116
Soneson, C., Love, M. I., & Robinson, M. D. (2015). Differential analyses for RNA-seq:
transcript-level estimates improve gene-level inferences. F1000Res, 4, 1521.
doi:10.12688/f1000research.7563.2
Srivastava, A., Malik, L., Smith, T., Sudbery, I., & Patro, R. (2019). Alevin efficiently
estimates accurate gene abundances from dscRNA-seq data. Genome biology,
20(1), 65. doi:10.1186/s13059-019-1670-y
Stallman RM, M. R. (1991). GNU Make—A Program for Directing Recompilation.
Retrieved from http://www.gnu.org/software/make/
Suva, M. L., & Tirosh, I. (2019). Single-Cell RNA Sequencing in Cancer: Lessons Learned
and
Emerging
Challenges.
Mol
Cell,
75(1),
7-12.
doi:10.1016/j.molcel.2019.05.003
Svensson, V., Vento-Tormo, R., & Teichmann, S. A. (2018). Exponential scaling of singlecell RNA-seq in the past decade. Nat Protoc, 13(4), 599-604.
doi:10.1038/nprot.2017.149
Szczurek, E., & Beerenwinkel, N. (2014). Modeling mutual exclusivity of cancer mutations.
PLoS Comput Biol, 10(3), e1003503. doi:10.1371/journal.pcbi.1003503
Tamborero, D., Gonzalez-Perez, A., Perez-Llamas, C., Deu-Pons, J., Kandoth, C.,
Reimand, J., . . . Lopez-Bigas, N. (2013). Comprehensive identification of
mutational cancer driver genes across 12 tumor types. Sci Rep, 3, 2650.
doi:10.1038/srep02650
Taub, M. A., Corrada Bravo, H., & Irizarry, R. A. (2010). Overcoming bias and systematic
errors in next generation sequencing data. Genome Medicine, 2(12), 87. Retrieved
from https://doi.org/10.1186/gm208
Teng, M., Love, M. I., Davis, C. A., Djebali, S., Dobin, A., Graveley, B. R., . . . Irizarry,
R. A. (2016). A benchmark for RNA-seq quantification pipelines. Genome Biol, 17,
74. doi:10.1186/s13059-016-0940-1
The Cancer Genome Atlas Research Network. (2012). Comprehensive genomic
characterization of squamous cell lung cancers. Nature, 489(7417), 519-525.
doi:10.1038/nature11404
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W.
M., . . . others. (2007). High-throughput oncogene mutation profiling in human
cancer. Nature genetics, 39(3), 347.
Tian, L., Dong, X., Freytag, S., Le Cao, K. A., Su, S., JalalAbadi, A., . . . Ritchie, M. E.
(2019). Benchmarking single cell RNA-sequencing analysis pipelines using

121

mixture control experiments. Nat Methods, 16(6), 479-487. doi:10.1038/s41592019-0425-8
Tian, L., Su, S., Dong, X., Amann-Zalcenstein, D., Biben, C., Seidi, A., . . . Ritchie, M. E.
(2018). scPipe: A flexible R/Bioconductor preprocessing pipeline for single-cell
RNA-sequencing
data.
PLoS
Comput
Biol,
14(8),
e1006361.
doi:10.1371/journal.pcbi.1006361
Tusher, V. G., Tibshirani, R., & Chu, G. (2001). Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci U S A, 98(9), 51165121. doi:10.1073/pnas.091062498
Vandin, F., Upfal, E., & Raphael, B. J. (2012). De novo discovery of mutated driver
pathways in cancer. Genome Research, 22(2), 375-385.
Venkatraman E. Seshan, A. O. DNAcopy: DNA copy number data analysis. R package
version 1.44.0.
Walport, L. J., Hopkinson, R. J., Chowdhury, R., Schiller, R., Ge, W., Kawamura, A., &
Schofield, C. J. (2016). Arginine demethylation is catalysed by a subset of JmjC
histone lysine demethylases. Nat Commun, 7, 11974. doi:10.1038/ncomms11974
Wang, Y., & Navin, N. E. (2015). Advances and applications of single-cell sequencing
technologies. Mol Cell, 58(4), 598-609. doi:10.1016/j.molcel.2015.05.005
Ward, P. S., Cross, J. R., Lu, C., Weigert, O., Abel-Wahab, O., Levine, R. L., . . . Thompson,
C. B. (2012). Identification of additional IDH mutations associated with
oncometabolite R(-)-2-hydroxyglutarate production. Oncogene, 31(19), 2491-2498.
doi:10.1038/onc.2011.416
Wolstencroft, K., Haines, R., Fellows, D., Williams, A., Withers, D., Owen, S., . . . Goble,
C. (2013). The Taverna workflow suite: designing and executing workflows of Web
Services on the desktop, web or in the cloud. Nucleic Acids Res, 41(Web Server
issue), W557-561. doi:10.1093/nar/gkt328
Xu, C. (2018). A review of somatic single nucleotide variant calling algorithms for nextgeneration sequencing data. Comput Struct Biotechnol J, 16, 15-24.
doi:10.1016/j.csbj.2018.01.003
Xu, H., Zong, H., Ma, C., Ming, X., Shang, M., Li, K., . . . Cao, L. (2017). Epidermal
growth factor receptor in glioblastoma. Oncology letters, 14(1), 512-516.
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., . . . Brown, M. (2012).
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycombindependent. Science, 338(6113), 1465-1469. doi:10.1126/science.1227604
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., . . . Bigner, D.
D. (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360(8), 765-773.
doi:10.1056/NEJMoa0808710
Youn, A., & Simon, R. (2011). Identifying cancer driver genes in tumor genome
sequencing
studies.
Bioinformatics,
27(2),
175-181.
doi:10.1093/bioinformatics/btq630
Yu, Y., Belazzougui, D., Qian, C., & Zhang, Q. (2018). Memory-Efficient and Ultra-Fast
Network Lookup and Forwarding Using Othello Hashing. IEEE/ACM Transactions
on Networking, 26(3), 1151-1164.
Yu, Y., Liu, J., Liu, X., Zhang, Y., Magner, E., Lehnert, E., . . . Liu, J. (2018). SeqOthello:
querying RNA-seq experiments at scale. Genome Biol, 19(1), 167.
doi:10.1186/s13059-018-1535-9
122

Zhang, L., Dong, X., Lee, M., Maslov, A. Y., Wang, T., & Vijg, J. (2019). Single-cell
whole-genome sequencing reveals the functional landscape of somatic mutations
in B lymphocytes across the human lifespan. Proceedings of the National Academy
of
Sciences,
116(18),
9014-9019.
Retrieved
from
https://www.pnas.org/content/116/18/9014
Zhao, S., Liu, J., Nanga, P., Liu, Y., Cicek, A. E., Knoblauch, N., . . . He, X. (2019).
Detailed modeling of positive selection improves detection of cancer driver genes.
Nat Commun, 10(1), 1-13.
Zheng, G. X., Terry, J. M., Belgrader, P., Ryvkin, P., Bent, Z. W., Wilson, R., . . . Bielas,
J. H. (2017). Massively parallel digital transcriptional profiling of single cells. Nat
Commun, 8, 14049. doi:10.1038/ncomms14049
Zhu, J., Sammons, M. A., Donahue, G., Dou, Z., Vedadi, M., Getlik, M., . . . Berger, S. L.
(2015). Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer
growth. Nature, 525(7568), 206-211. doi:10.1038/nature15251

123

VITA
Jinpeng Liu
•

Education
- M.S. in Computer Science Jan. 2013 - June. 2014
University of Kentucky, Lexington, KY, USA
- M.S. in Pharmaceutical Science Sep. 2006 - July. 2009
Shanxi Medical University, Taiyuan, Shanxi, China
- B.S. in Biological Engineering Sep. 2002 - July. 2006
Beijing Institute of Technology, Beijing, China

•

Employment History
- Bioinformatics Analyst Senior, June 2014 - Present
University of Kentucky, Lexington, KY, USA
- Research Assistant, Jan. 2013 - June. 2014
University of Kentucky, Lexington, KY, USA
- Shanxi Institute for Food and Drug Control, Sep. 2006 - Jan. 2011
Taiyuan, Shanxi, China

•

Publications
1. Liu J, Liu X, Yu Y, Wang C, Liu JZ: FastCount: A Fast Gene Count Software for
Single-cell RNA-seq Data. Manuscript in preparation 2021.
2. Chen F, Byrd A, Liu J, Robert M. Flight, Tanner J. DuCote, Mojtaba Bakhtiari,
Xiulong Song, Abigail R. Edgin,Alexsandr Lukyanchuk, Danielle T. Dixon, Stuart
H. Orkin5, Hunter N.B. Mosely, Chi Wang, Christine Fillmore Brainson: Polycomb
deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors.
Nature Communications. Manuscript in revision 2021.
3. Liu S*, Liu J*, Xie Y, Zhai T, Hinderer EW, Stromberg AJ, Vanderford NL,
124

Kolesar JM, Moseley HNB, Chen L, Liu C, Wang C: MEScan: a powerful
statistical framework for Genome-Scale mutual exclusivity analysis of cancer
mutations. Bioinformatics (Oxford, England) 2020.
4. Lin N*, Liu J*, Castle J, Wan J, Shendre A, Liu Y, Wang C, He C: Genome-wide
DNA methylation profiling in human breast tissue by illumina TruSeq methyl
capture EPIC sequencing and infinium methylationEPIC beadchip microarray.
Epigenetics 2020:1-16.
5. Conroy L, Youn L, Stanback A, Austin L. G, Liu J, Liu JZ, Allison D, Sun C. R:
Mass spectrometry imaging of N-glycans reveals racial discrepancies in low grade
prostate tumors. The Journal of Clinical Investigation. Manuscript in review 2020.
6. Liu J*, Murali T*, Yu T*, Liu C, Sivakumaran TA, Moseley HNB, Zhulin IB,
Weiss HL, Durbin EB, Ellingson SR, Liu J, Huang B, Hallahan BJ, Horbinski CM,
Hodges K, Napier DL, Bocklage T, Mueller J, Vanderford NL, Fardo DW, Wang
C, Arnold SM: Characterization of Squamous Cell Lung Cancers from Appalachian
Kentucky. Cancer Epidemiol Biomarkers Prev 2019, 28(2):348-356.
7. Yu Y, Liu J, Liu X, Zhang Y, Magner E, Lehnert E, Qian C, Liu J: SeqOthello:
querying RNA-seq experiments at scale. Genome biology 2018, 19(1):167.
8. Liu X, Yu Y, Liu J, Elliott CF, Qian C, Liu J: A novel data structure to support
ultra-fast taxonomic classification of metagenomic sequences with k-mer
signatures. Bioinformatics (Oxford, England) 2018, 34(1):171-178.
9. Wang M, Yu T, Liu J, Chen L, Stromberg AJ, Villano JL, Arnold SM, Liu C, Wang
C: A probabilistic method for leveraging functional annotations to enhance
estimation of the temporal order of pathway mutations during carcinogenesis. BMC
bioinformatics 2019, 20(1):620
10. Zhong Y, Mohan K, Liu J, Al-Attar A, Lin P, Flight RM, Sun Q, Warmoes MO,
Deshpande RR, Liu H: Loss of CLN3, the gene mutated in juvenile neuronal ceroid
lipofuscinosis, leads to metabolic impairment and autophagy induction in retina
pigment epithelium. BBA - Molecular Basis of Disease 2020.
11. Tripathi R, Liu Z, Jain A, Lyon A, Meeks C, Richards D, Liu J, He D, Wang C,
Nespi M, Rymar A, Wang P, Wilson M, Plattner R: Combating acquired resistance
to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of
125

MEK/ERK/MYC signaling. Nature communications 2020, 11(1):5463.
12. Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, Kong Y, Li C, Zhang Z, Liu J,
Jones K, Napier D, Lee EY, Wang C, Liu X: p300/CBP inhibition enhances the
efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Oncogene 2020, 39(19):3939-3951.
13. Li J, Li X, Song J, Yan B, Rock SA, Jia J, Liu J, Wang C, Weiss T, Weiss HL, Gao
T, Alam A, Evers BM: Absence of neurotensin attenuates intestinal dysbiosis and
inflammation by maintaining Mmp7/alpha-defensin axis in diet-induced obese
mice. FASEB J 2020, 34(6):8596-8610.
14. Liu L, Qi L, Knifley T, Piecoro DW, Rychahou P, Liu J, Mitov MI, Martin J, Wang
C, Wu J, Weiss HL, Butterfield DA, Evers BM, O'Connor KL, Chen M: S100A4
alters metabolism and promotes invasion of lung cancer cells by up-regulating
mitochondrial complex I protein NDUFS2. J Biol Chem 2019, 294(18):7516-7527.
15. Liu L, Qi L, Knifley T, Piecoro DW, Rychahou P, Liu J, Mitov MI, Martin J, Wang
C, Wu J: S100A4 alters mitochondrial metabolism to promote invasion and
metastasis of non-small cell lung cancer cells through upregulation of NDUFS2. In.:
AACR; 2019.
16. Li H, Li J, Han R, Deng X, Shi J, Huang H, Hamad N, McCaughley A, Liu J, Wang
C, Chen K, Wei D, Qiang J, Thatcher S, Wu Y, Liu C, Thibault O, Wei X, Chen S,
Qian H, Zhou BP, Xu P, Yang XH: Deletion of tetraspanin CD151 alters the Wnt
oncogene-induced mammary tumorigenesis: A cell type-linked function and
signaling. Neoplasia 2019, 21(12):1151-1163.
17. Jafari N, Drury J, Morris AJ, Onono FO, Stevens PD, Gao T, Liu J, Wang C, Lee
EY, Weiss HL, Evers BM, Zaytseva YY: De Novo Fatty Acid Synthesis-Driven
Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer. Mol
Cancer Res 2019, 17(1):140-152.
18. Zaytseva YY, Rychahou PG, Le AT, Scott TL, Flight RM, Kim JT, Harris J, Liu J,
Wang C, Morris AJ, Sivakumaran TA, Fan T, Moseley H, Gao T, Lee EY, Weiss
HL, Heuer TS, Kemble G, Evers M: Preclinical evaluation of novel fatty acid
synthase inhibitors in primary colorectal cancer cells and a patient-derived
xenograft model of colorectal cancer. Oncotarget 2018, 9(37):24787-24800.
126

19. Wang Q, Kim JT, Zhou Y, Li C, Liu J, Wang C, Evers BM: 87–Mir-181A-5P
Contributes to Intestinal Cell Differentiation. Gastroenterology 2019, 156(6):S-19S-20.
20. Thampi P, Liu J, Zeng Z, MacLeod JN: Changes in the appendicular skeleton
during metamorphosis in the axolotl salamander (Ambystoma mexicanum). Journal
of anatomy 2018, 233(4):468-477.
21. Tripathi R, Fiore LS, Richards DL, Yang Y, Liu J, Wang C, Plattner R: Abl and
Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and
metastasis. Sci Signal 2018, 11(518).
22. Chaiswing L, Thorson J, Xu FF, Wang C, Liu J, Clair DS, Clair WS: RelB-BLNK
axis: a novel determinant of cell fate. Free Radical Biology and Medicine 2018,
128:S64-S65.
23. Wang Q, Zhu J, Wang YW, Dai Y, Wang YL, Wang C, Liu J, Baker A, Colburn
NH, Yang HS: Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit
invasion in colon carcinoma. Oncogene 2017, 36(45):6225-6234
24. Oben KZ, Alhakeem SS, McKenna MK, Brandon JA, Mani R, Noothi SK, Liu J,
Akunuru S, Dhar SK, Singh IP: Oxidative stress-induced JNK/AP-1 signaling is a
major pathway involved in selective apoptosis of myelodysplastic syndrome cells
by Withaferin-A. Oncotarget 2017, 8(44):77436.
25. Carpenter BL, Liu J, Qi L, Wang C, O’Connor KL: Integrin α6β4 Upregulates
Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA
Demethylation and Promotes Genome-wide DNA Hypomethylation. Scientific
reports 2017, 7(1):1-14.
26. Yu T, Chen X, Zhang W, Liu J, Avdiushko R, Napier DL, Liu AX, Neltner JM,
Wang C, Cohen D, Liu C: KLF4 regulates adult lung tumor-initiating cells and
represses K-Ras-mediated lung cancer. Cell Death Differ 2016, 23(2):207-215.
27. Wang H, Horbinski C, Wu H, Liu Y, Sheng S, Liu J, Weiss H, Stromberg AJ,
Wang C: NanoStringDiff: a novel statistical method for differential expression
analysis based on NanoString nCounter data. Nucleic acids research 2016,
44(20):e151.
28. Wang C, Liu J, Fardo DW: Causal effect estimation in sequencing studies: a
127

Bayesian method to account for confounder adjustment uncertainty. In: BMC
proceedings: 2016: BioMed Central; 2016: 411-415.
29. Rouchka EC, Jeoung M, Jang ER, Liu J, Wang C, Li X, Galperin E: Data set for
transcriptional response to depletion of the Shoc2 scaffolding protein. Data Brief
2016, 7:770-778.
30. Oben KZ, Gachuki B, Akunuru S, Liu J, Brandon J, St Clair D, Wang C, Geiger H,
Gupta R, Bondada S: Growth inhibitory effects of Withaferin A on MDS-L cells–A
human 5q Myelodysplastic Syndrome (MDS) cell line. In.: Am Assoc Immnol;
2016.
31. Jeoung M, Jang ER, Liu J, Wang C, Rouchka EC, Li X, Galperin E: Shoc2tranduced ERK1/2 motility signals—novel insights from functional genomics.
Cellular signalling 2016, 28(5):448-459.
32. Gal TS, Ellingson SR, Wang C, Liu J, Jarrett SG, D'Orazio JA: Using large public
data repositories to discover novel genetic mutations with prospective links to
melanoma. BMC bioinformatics 2015, 16(15):1-3.

128

